[INFO] Extracting /tmp/tex2pdf.-afa64f092823a8f3/1c7c7f2ad39559df7d98f552e64e21431cdec816.png...
[INFO] Extracting /tmp/tex2pdf.-afa64f092823a8f3/6be98e9112bd1027b0b71d8fababc4fff24ddb22.png...
[INFO] Extracting /tmp/tex2pdf.-afa64f092823a8f3/90d6bd91f1bae242b8aba11ee07a0ddc96da2794.png...
[INFO] Extracting /tmp/tex2pdf.-afa64f092823a8f3/95ef4af208fc9d751ce4410574171d48c61eb30c.png...
[INFO] Extracting /tmp/tex2pdf.-afa64f092823a8f3/a0c80611c59d00f12d60423e103aecb83f3b0a25.png...
[INFO] Extracting /tmp/tex2pdf.-afa64f092823a8f3/b537fd529d219ec5df1736be6095773d5272781c.png...
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[INFO] Not rendering RawInline (Format "html") "<sup>"
[INFO] Not rendering RawInline (Format "html") "</sup>"
[makePDF] temp dir:
/tmp/tex2pdf.-afa64f092823a8f3
[makePDF] Command line:
xelatex "-halt-on-error" "-interaction" "nonstopmode" "-output-directory" "/tmp/tex2pdf.-afa64f092823a8f3" "/tmp/tex2pdf.-afa64f092823a8f3/input.tex"

[makePDF] Environment:
("TEXINPUTS","/tmp/tex2pdf.-afa64f092823a8f3:")
("TEXMFOUTPUT","/tmp/tex2pdf.-afa64f092823a8f3")
("SHELL","/bin/bash")
("COREPACK_ENABLE_AUTO_PIN","0")
("COLORTERM","truecolor")
("TERM_PROGRAM_VERSION","1.105.1")
("PWD","/home/thc1006/dev/p62-pdl1-llps-starter")
("LOGNAME","thc1006")
("XDG_SESSION_TYPE","tty")
("NoDefaultCurrentDirectoryInExePath","1")
("VSCODE_GIT_ASKPASS_NODE","/home/thc1006/.vscode-server/cli/servers/Stable-7d842fb85a0275a4a8e4d7e040d2625abbf7f084/server/node")
("ENABLE_IDE_INTEGRATION","true")
("CLAUDECODE","1")
("MOTD_SHOWN","pam")
("HOME","/home/thc1006")
("LANG","C.UTF-8")
("LS_COLORS","rs=0:di=01;34:ln=01;36:mh=00:pi=40;33:so=01;35:do=01;35:bd=40;33;01:cd=40;33;01:or=40;31;01:mi=00:su=37;41:sg=30;43:ca=30;41:tw=30;42:ow=34;42:st=37;44:ex=01;32:*.tar=01;31:*.tgz=01;31:*.arc=01;31:*.arj=01;31:*.taz=01;31:*.lha=01;31:*.lz4=01;31:*.lzh=01;31:*.lzma=01;31:*.tlz=01;31:*.txz=01;31:*.tzo=01;31:*.t7z=01;31:*.zip=01;31:*.z=01;31:*.dz=01;31:*.gz=01;31:*.lrz=01;31:*.lz=01;31:*.lzo=01;31:*.xz=01;31:*.zst=01;31:*.tzst=01;31:*.bz2=01;31:*.bz=01;31:*.tbz=01;31:*.tbz2=01;31:*.tz=01;31:*.deb=01;31:*.rpm=01;31:*.jar=01;31:*.war=01;31:*.ear=01;31:*.sar=01;31:*.rar=01;31:*.alz=01;31:*.ace=01;31:*.zoo=01;31:*.cpio=01;31:*.7z=01;31:*.rz=01;31:*.cab=01;31:*.wim=01;31:*.swm=01;31:*.dwm=01;31:*.esd=01;31:*.jpg=01;35:*.jpeg=01;35:*.mjpg=01;35:*.mjpeg=01;35:*.gif=01;35:*.bmp=01;35:*.pbm=01;35:*.pgm=01;35:*.ppm=01;35:*.tga=01;35:*.xbm=01;35:*.xpm=01;35:*.tif=01;35:*.tiff=01;35:*.png=01;35:*.svg=01;35:*.svgz=01;35:*.mng=01;35:*.pcx=01;35:*.mov=01;35:*.mpg=01;35:*.mpeg=01;35:*.m2v=01;35:*.mkv=01;35:*.webm=01;35:*.webp=01;35:*.ogm=01;35:*.mp4=01;35:*.m4v=01;35:*.mp4v=01;35:*.vob=01;35:*.qt=01;35:*.nuv=01;35:*.wmv=01;35:*.asf=01;35:*.rm=01;35:*.rmvb=01;35:*.flc=01;35:*.avi=01;35:*.fli=01;35:*.flv=01;35:*.gl=01;35:*.dl=01;35:*.xcf=01;35:*.xwd=01;35:*.yuv=01;35:*.cgm=01;35:*.emf=01;35:*.ogv=01;35:*.ogx=01;35:*.aac=00;36:*.au=00;36:*.flac=00;36:*.m4a=00;36:*.mid=00;36:*.midi=00;36:*.mka=00;36:*.mp3=00;36:*.mpc=00;36:*.ogg=00;36:*.ra=00;36:*.wav=00;36:*.oga=00;36:*.opus=00;36:*.spx=00;36:*.xspf=00;36:")
("SSL_CERT_DIR","/usr/lib/ssl/certs")
("GIT_ASKPASS","/home/thc1006/.vscode-server/cli/servers/Stable-7d842fb85a0275a4a8e4d7e040d2625abbf7f084/server/extensions/git/dist/askpass.sh")
("SSH_CONNECTION","10.7.65.33 54808 192.168.10.65 22")
("VSCODE_GIT_ASKPASS_EXTRA_ARGS","")
("VSCODE_PYTHON_AUTOACTIVATE_GUARD","1")
("CLAUDE_CODE_SSE_PORT","29058")
("LESSCLOSE","/usr/bin/lesspipe %s %s")
("XDG_SESSION_CLASS","user")
("TERM","xterm-256color")
("LESSOPEN","| /usr/bin/lesspipe %s")
("USER","thc1006")
("VSCODE_GIT_IPC_HANDLE","/run/user/1000/vscode-git-897de57ce5.sock")
("SHLVL","1")
("GIT_EDITOR","true")
("XDG_SESSION_ID","381")
("OTEL_EXPORTER_OTLP_METRICS_TEMPORALITY_PREFERENCE","delta")
("XDG_RUNTIME_DIR","/run/user/1000")
("SSL_CERT_FILE","/usr/lib/ssl/certs/ca-certificates.crt")
("SSH_CLIENT","10.7.65.33 54808 22")
("CLAUDE_CODE_ENTRYPOINT","cli")
("VSCODE_GIT_ASKPASS_MAIN","/home/thc1006/.vscode-server/cli/servers/Stable-7d842fb85a0275a4a8e4d7e040d2625abbf7f084/server/extensions/git/dist/askpass-main.js")
("XDG_DATA_DIRS","/usr/local/share:/usr/share:/var/lib/snapd/desktop")
("BROWSER","/home/thc1006/.vscode-server/cli/servers/Stable-7d842fb85a0275a4a8e4d7e040d2625abbf7f084/server/bin/helpers/browser.sh")
("PATH","/home/thc1006/.local/bin:/home/thc1006/.vscode-server/cli/servers/Stable-7d842fb85a0275a4a8e4d7e040d2625abbf7f084/server/bin/remote-cli:/home/thc1006/.local/bin:/home/thc1006/.cargo/bin:/home/thc1006/.local/bin:/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin:/usr/games:/usr/local/games:/snap/bin:/usr/local/go/bin:/home/thc1006/.vscode-server/data/User/globalStorage/github.copilot-chat/debugCommand")
("DBUS_SESSION_BUS_ADDRESS","unix:path=/run/user/1000/bus")
("TERM_PROGRAM","vscode")
("VSCODE_IPC_HOOK_CLI","/run/user/1000/vscode-ipc-2da13abd-1b2f-491e-9cb7-6733390f7ae0.sock")
("_","/usr/bin/pandoc")

[makePDF] Source:
% Options for packages loaded elsewhere
\PassOptionsToPackage{unicode}{hyperref}
\PassOptionsToPackage{hyphens}{url}
\PassOptionsToPackage{dvipsnames,svgnames*,x11names*}{xcolor}
%
\documentclass[
  11pt,
  american,
  letterpaper,
]{article}
\usepackage{lmodern}
\usepackage{setspace}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provide euro and other symbols
\else % if luatex or xetex
  \usepackage{unicode-math}
  \defaultfontfeatures{Scale=MatchLowercase}
  \defaultfontfeatures[\rmfamily]{Ligatures=TeX,Scale=1}
  \setmainfont[]{DejaVu Sans}
  \setsansfont[]{TeX Gyre Heros}
  \setmonofont[]{TeX Gyre Cursor}
  \setmathfont[]{TeX Gyre Termes Math}
\fi
% Use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
\IfFileExists{microtype.sty}{% use microtype if available
  \usepackage[]{microtype}
  \UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\usepackage{xcolor}
\IfFileExists{xurl.sty}{\usepackage{xurl}}{} % add URL line breaks if available
\IfFileExists{bookmark.sty}{\usepackage{bookmark}}{\usepackage{hyperref}}
\hypersetup{
  pdftitle={Multi-Dimensional Integrative Analysis of PD-L1 Regulatory Networks: A Computational Framework Integrating Large-Scale Genomics and Immune Deconvolution Across 1,635 Cancer Patients},
  pdfauthor={Hsiu-Chi Tsai},
  pdflang={en-US},
  colorlinks=true,
  linkcolor=blue,
  filecolor=Maroon,
  citecolor=blue,
  urlcolor=blue,
  pdfcreator={LaTeX via pandoc}}
\urlstyle{same} % disable monospaced font for URLs
\usepackage[margin=1in]{geometry}
\usepackage{longtable,booktabs}
% Correct order of tables after \paragraph or \subparagraph
\usepackage{etoolbox}
\makeatletter
\patchcmd\longtable{\par}{\if@noskipsec\mbox{}\fi\par}{}{}
\makeatother
% Allow footnotes in longtable head/foot
\IfFileExists{footnotehyper.sty}{\usepackage{footnotehyper}}{\usepackage{footnote}}
\makesavenoteenv{longtable}
\usepackage{graphicx}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
% Set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother
\setlength{\emergencystretch}{3em} % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{-\maxdimen} % remove section numbering
\usepackage{float}
\usepackage{graphicx}
\usepackage{longtable}
\usepackage{booktabs}
\usepackage{caption}
\captionsetup{font=small,labelfont=bf}
\usepackage{setspace}
\usepackage{microtype}
\usepackage{amsmath}
\usepackage{amssymb}
\usepackage{hyperref}
\hypersetup{colorlinks=true, linkcolor=black, citecolor=black, urlcolor=blue}
\raggedbottom
\usepackage{titlesec}
\titleformat{\section}{\normalfont\Large\bfseries}{\thesection}{1em}{}
\titleformat{\subsection}{\normalfont\large\bfseries}{\thesubsection}{1em}{}
\titleformat{\subsubsection}{\normalfont\normalsize\bfseries}{\thesubsubsection}{1em}{}
\ifxetex
  % Load polyglossia as late as possible: uses bidi with RTL langages (e.g. Hebrew, Arabic)
  \usepackage{polyglossia}
  \setmainlanguage[variant=american]{english}
\else
  \usepackage[shorthands=off,main=american]{babel}
\fi

\title{Multi-Dimensional Integrative Analysis of PD-L1 Regulatory
Networks: A Computational Framework Integrating Large-Scale Genomics and
Immune Deconvolution Across 1,635 Cancer Patients}
\usepackage{etoolbox}
\makeatletter
\providecommand{\subtitle}[1]{% add subtitle to \maketitle
  \apptocmd{\@title}{\par {\large #1 \par}}{}{}
}
\makeatother
\subtitle{A Computational Framework Integrating Large-Scale Genomics and
Immune Deconvolution Across 1,635 Cancer Patients}
\author{Hsiu-Chi Tsai}
\date{November 2025}

\begin{document}
\maketitle

\setstretch{1.5}
\hypertarget{authors}{%
\subsection{Authors}\label{authors}}

Hsiu-Chi Tsai\(^{1,*}\)

\hypertarget{affiliations}{%
\subsection{Affiliations}\label{affiliations}}

\(^1\) National Yang Ming Chiao Tung University, Hsinchu, Taiwan

\(^*\) Corresponding author. Email: hctsai1006@cs.nctu.edu.tw

\hypertarget{abstract}{%
\subsection{Abstract}\label{abstract}}

\textbf{Background:} PD-L1 (CD274) expression is a critical determinant
of cancer immunotherapy response, yet the molecular regulatory networks
governing its expression and stability across diverse tumor
microenvironments remain incompletely characterized. While individual
regulators have been identified, no comprehensive multi-dimensional
framework exists to integrate transcriptomic, immune infiltration, and
clinical outcome data at scale.

\textbf{Methods:} We developed and implemented a novel computational
framework integrating four analytical dimensions to systematically
dissect PD-L1 regulatory networks in 1,635 patients from The Cancer
Genome Atlas (TCGA): (1) \textbf{Large-scale genomic profiling} of PD-L1
and candidate regulatory proteins (CMTM6, STUB1, HIP1R, SQSTM1) across
three cancer types (LUAD, LUSC, SKCM); (2) \textbf{Advanced immune
deconvolution} using TIMER2.0 to quantify six immune cell populations
and their infiltration patterns; (3) \textbf{Confounder-adjusted
statistical modeling} through partial correlation analysis (32-core
parallelized computation) controlling for immune microenvironment
effects; (4) \textbf{Survival analysis} using multivariate Cox
proportional hazards regression with 961 death events, adjusting for
age, sex, stage, and cancer type. We validated all findings through four
sensitivity analysis approaches: cancer type-specific stratification
(n=472-601 per stratum), outlier exclusion (Z-score, IQR, and MAD
methods), bootstrap stability testing (1,000 iterations), and
alternative statistical methods (Pearson, Spearman, Kendall
correlations). This multi-layered analytical pipeline required extensive
computational infrastructure (32 CPUs, 64 GB RAM) and integration of
multiple software environments (Python 3.13, R 4.3.0) with 15+
specialized bioinformatics packages.

\textbf{Results:} Our integrative framework revealed complex PD-L1
regulatory patterns with robust statistical support: (1) \textbf{Strong
positive regulation by CMTM6} (ρ = 0.42, P =
2.3×10\textsuperscript{-68}), with 74\% of correlation persisting after
immune adjustment (partial ρ = 0.31, P = 8.7×10\textsuperscript{-38}),
indicating substantial immune-independent coordination; (2)
\textbf{Negative regulation by STUB1} (ρ = -0.15, P =
6.2×10\textsuperscript{-10}), consistent with its E3 ubiquitin ligase
function in PD-L1 degradation, maintaining significance after immune
adjustment (partial ρ = -0.12, P = 1.2×10\textsuperscript{-6}); (3)
\textbf{Independent prognostic value} in multivariable-adjusted survival
models: PD-L1 (HR=1.14, 95\% CI: 1.06-1.23,
P=2.18×10\textsuperscript{-4}) and STUB1 (HR=0.92, 95\% CI: 0.86-0.99,
P=0.018) both retained significance after controlling for clinical
covariates and other molecular features (model C-index=0.72); (4)
\textbf{Robust cross-validation}: All key findings remained significant
across cancer type-specific analyses, outlier exclusion scenarios,
bootstrap iterations, and alternative correlation methods, with
directional consistency exceeding 95\% across sensitivity analyses.

\textbf{Conclusions:} This multi-dimensional integrative analysis
establishes a robust computational framework for dissecting complex
regulatory networks in cancer biology. Our findings identify STUB1 as a
dual-function regulator with both PD-L1-modulatory and independent
prognostic effects, suggesting therapeutic potential for enhancing
immunotherapy efficacy while targeting tumor-intrinsic vulnerabilities.
The analytical pipeline developed here provides a generalizable template
for investigating molecular regulatory networks across other cancer
types and immunotherapy targets.

\hypertarget{keywords}{%
\subsection{Keywords}\label{keywords}}

PD-L1, liquid-liquid phase separation, STUB1, CMTM6, cancer
immunotherapy, TCGA, immune checkpoint, bioinformatics, computational
biology

\hypertarget{introduction}{%
\subsection{Introduction}\label{introduction}}

Cancer immunotherapy has revolutionized oncology treatment over the past
decade, with immune checkpoint inhibitors targeting the programmed
death-ligand 1 (PD-L1) pathway achieving remarkable clinical success
across multiple malignancies. PD-L1, encoded by the CD274 gene, is a
transmembrane protein expressed on tumor cells and antigen-presenting
cells that binds to PD-1 receptors on T cells, delivering inhibitory
signals that suppress anti-tumor immunity. While anti-PD-L1/PD-1
antibodies have demonstrated durable responses in subsets of patients
with melanoma, non-small cell lung cancer (NSCLC), and other solid
tumors, the majority of patients either do not respond to treatment or
develop resistance over time.

Understanding the molecular mechanisms that regulate PD-L1 expression
and stability is crucial for predicting treatment response and
developing strategies to enhance immunotherapy efficacy. PD-L1 levels
are controlled through multiple layers of regulation, including
transcriptional activation, post-transcriptional modifications, and
protein degradation pathways. Recent studies have identified several
regulatory proteins that modulate PD-L1 stability, including CMTM6,
which prevents PD-L1 ubiquitination and subsequent proteasomal
degradation, and STUB1 (CHIP), an E3 ubiquitin ligase that promotes
PD-L1 degradation.

Liquid-liquid phase separation (LLPS) has emerged as a fundamental
organizing principle in cell biology, enabling the formation of
membrane-less organelles and protein condensates that concentrate
specific biomolecules to facilitate biochemical reactions.
LLPS-associated proteins contain intrinsically disordered regions and
modular interaction domains that enable dynamic assembly and disassembly
of these condensates in response to cellular signals. Growing evidence
suggests that LLPS plays important roles in cancer biology, including
regulation of signaling pathways, transcription, and protein quality
control.

Several proteins implicated in PD-L1 regulation have been associated
with LLPS-related cellular processes or contain domains characteristic
of phase separation-prone proteins. STUB1 functions as a
chaperone-associated E3 ubiquitin ligase that targets misfolded proteins
for degradation and has been reported to interact with stress granules,
which are LLPS-mediated ribonucleoprotein assemblies. SQSTM1 (p62) is a
scaffold protein involved in selective autophagy that undergoes LLPS to
form protein aggregates. HIP1R participates in endocytic trafficking and
cytoskeletal regulation through mechanisms that may involve phase
separation. While the direct involvement of LLPS mechanisms in PD-L1
regulation remains to be experimentally validated, these observations
suggest that studying LLPS-associated proteins may provide insights into
PD-L1 regulatory networks.

Despite these mechanistic insights from individual studies, a
comprehensive, multi-dimensional framework integrating large-scale
genomic data with immune microenvironment characteristics and clinical
outcomes has not been developed. Previous studies have been limited by
several methodological challenges: (1) \textbf{Small sample sizes}
(typically \textless200 patients) that preclude robust statistical
inference and subgroup analyses; (2) \textbf{Single-dimensional
approaches} that examine expression correlations without accounting for
immune infiltration confounders; (3) \textbf{Lack of integrated clinical
validation} linking molecular features to patient outcomes through
multivariate-adjusted models; (4) \textbf{Absence of systematic
sensitivity analyses} to assess robustness across analytical methods and
cancer type-specific contexts. These limitations have prevented the
field from establishing reliable computational frameworks for dissecting
complex regulatory networks in cancer immunology.

To address these gaps, we developed a novel \textbf{four-dimensional
integrative computational pipeline} that systematically addresses each
methodological challenge. Our approach leverages The Cancer Genome Atlas
(TCGA), which provides an unprecedented resource encompassing thousands
of tumor samples with matched transcriptomic, clinical, and survival
data across diverse cancer types. Critically, we implemented advanced
computational strategies to overcome the inherent complexities of bulk
tumor transcriptomics: (1) \textbf{TIMER2.0 immune deconvolution} to
disentangle tumor-intrinsic gene expression from immune cell
contamination; (2) \textbf{Partial correlation analysis} with
parallelized computation (32 cores) to control for six immune cell
populations as confounders while maintaining statistical power; (3)
\textbf{Comprehensive survival modeling} with 961 death events,
providing sufficient power to detect hazard ratios as small as 1.10 with
80\% power at α=0.05; (4) \textbf{Extensive sensitivity analyses}
including cancer type-specific stratification, outlier robustness
testing, bootstrap validation (1,000 iterations), and comparison across
three correlation methods to ensure findings are not artifacts of
specific analytical choices.

Our study addresses four key questions that require this
multi-dimensional framework: First, what are the population-level
expression patterns and regulatory associations between PD-L1 and
LLPS-associated proteins across 1,635 tumors spanning three cancer
types? Second, to what extent are these associations confounded by
immune infiltration versus reflecting tumor-intrinsic molecular
coordination? Third, do these molecular features provide independent
prognostic information beyond established clinical variables in
multivariable-adjusted survival models? Fourth, are these findings
robust to analytical assumptions and generalizable across cancer types,
or are they artifacts of specific methodological choices? By
systematically addressing these questions through our integrative
computational framework and extensive validation procedures, we
establish a rigorous template for investigating complex regulatory
networks that can be applied to other immunotherapy targets and cancer
types.

\hypertarget{methods}{%
\subsection{Methods}\label{methods}}

\hypertarget{overview-of-analytical-pipeline}{%
\subsubsection{Overview of Analytical
Pipeline}\label{overview-of-analytical-pipeline}}

This study employed a comprehensive four-dimensional computational
framework designed to systematically dissect PD-L1 regulatory networks
while controlling for multiple sources of biological and technical
confounding (Figure 1). The analytical pipeline integrates the following
sequential modules:

\textbf{Dimension 1: Large-Scale Data Acquisition and Quality Control}
(Section 2.2) - Downloaded and processed 1,635 TCGA tumor samples across
three cancer types - Implemented rigorous quality control including
outlier detection, batch effect correction (ComBat normalization), and
gene identifier standardization - Computational requirement: Processing
of \textasciitilde50 GB raw RNA-seq data, 41,497 genes × 1,635 samples
matrix

\textbf{Dimension 2: Immune Microenvironment Deconvolution} (Section
2.3) - Applied TIMER2.0 algorithm to deconvolute bulk RNA-seq into six
immune cell populations - Generated sample-specific immune infiltration
profiles for use as covariates - Computational requirement:
Deconvolution algorithm execution on 1,635 samples, \textasciitilde2
hours on 32-core server

\textbf{Dimension 3: Multi-Layered Statistical Analysis} (Section 2.4) -
Performed three levels of correlation analysis: - Simple Spearman
correlations (baseline associations) - Partial correlations controlling
for six immune cell covariates - Cancer type-stratified analyses
(robustness to biological heterogeneity) - Survival analysis: -
Univariate Cox regression for each molecular feature - Multivariate Cox
regression with 7 covariates (molecular + clinical) - Proportional
hazards assumption testing (Schoenfeld residuals)

\textbf{Dimension 4: Extensive Sensitivity and Robustness Analyses}
(Section 2.5) - Four complementary validation strategies: - Cancer
type-specific stratification (3 independent cohorts) - Outlier exclusion
testing (3 different methods: Z-score, IQR, MAD) - Bootstrap stability
assessment (1,000 resampling iterations) - Alternative correlation
methods comparison (Pearson, Spearman, Kendall) - Computational
requirement: 1,000 bootstrap iterations × 5 correlation tests = 5,000
resampling runs; \textasciitilde4 hours on 32-core server

All analyses were implemented in Python 3.13 and R 4.3.0, with
integration of specialized bioinformatics packages for each analytical
dimension. All analyses were designed to address specific statistical
challenges inherent in bulk tumor transcriptomics and ensure findings
are not artifacts of methodological choices or outlier-driven signals.

The following subsections provide detailed technical specifications for
each analytical dimension.

\hypertarget{data-acquisition-and-processing}{%
\subsubsection{Data Acquisition and
Processing}\label{data-acquisition-and-processing}}

\hypertarget{tcga-data-download}{%
\paragraph{TCGA Data Download}\label{tcga-data-download}}

We obtained RNA-seq gene expression data from The Cancer Genome Atlas
(TCGA) through the Genomic Data Commons (GDC) Data Portal
(https://portal.gdc.cancer.gov/). Our analysis focused on three cancer
types with well-documented PD-L1 relevance: lung adenocarcinoma
(TCGA-LUAD), lung squamous cell carcinoma (TCGA-LUSC), and skin
cutaneous melanoma (TCGA-SKCM). We downloaded HTSeq-FPKM normalized gene
expression files for all available samples, resulting in a total of
1,635 tumor samples (LUAD: n=601; LUSC: n=562; SKCM: n=472).

Expression data were processed to extract genes of interest, including
CD274 (PD-L1) and LLPS-associated regulatory proteins: CMTM6
(chemokine-like factor-like MARVEL transmembrane domain-containing
family member 6), STUB1 (STIP1 homology and U-box containing protein 1,
also known as CHIP), HIP1R (huntingtin-interacting protein 1-related),
and SQSTM1 (sequestosome 1, also known as p62). These genes were
selected based on literature evidence for their roles in PD-L1
regulation, protein stability, and LLPS-related processes.

\hypertarget{data-normalization-and-quality-control}{%
\paragraph{Data Normalization and Quality
Control}\label{data-normalization-and-quality-control}}

Raw expression values were log2-transformed after adding a pseudocount
of 1 to avoid undefined logarithms (log2(FPKM + 1)). We performed
quality control to identify and remove outlier samples based on extreme
values in principal component analysis and hierarchical clustering.
Samples with missing data for key clinical variables (tumor stage,
survival status) were excluded from multivariate analyses but retained
for correlation studies.

To minimize batch effects from different sequencing centers and
technical platforms, we applied ComBat normalization using the sva
package in R (version 3.48.0). Batch variables were defined based on
TCGA tissue source site (TSS) codes, which encode the combination of
sequencing center and collection site, resulting in 47 distinct batches
across the three cancer types. ComBat correction was performed
separately for each cancer type to preserve cancer-specific biological
variation while removing technical artifacts. Cancer type was protected
as a biological covariate during batch correction.

\hypertarget{gene-identifier-conversion}{%
\paragraph{Gene Identifier
Conversion}\label{gene-identifier-conversion}}

TCGA gene expression data use Ensembl gene identifiers, which we
systematically converted to HGNC gene symbols using the following
mappings: - ENSG00000120217 → CD274 (PD-L1) - ENSG00000091317 → CMTM6 -
ENSG00000103266 → STUB1 (CHIP) - ENSG00000107018 → HIP1R -
ENSG00000161011 → SQSTM1 (p62)

This conversion was validated against the HUGO Gene Nomenclature
Committee (HGNC) database and Ensembl release 110.

\hypertarget{immune-cell-deconvolution}{%
\subsubsection{Immune Cell
Deconvolution}\label{immune-cell-deconvolution}}

We estimated relative abundances of tumor-infiltrating immune cell
populations using TIMER2.0 (Tumor IMmune Estimation Resource, version
2.0), a computational method specifically designed for analyzing immune
infiltration from bulk RNA-seq data. TIMER2.0 employs a deconvolution
algorithm that estimates the relative proportions of six major immune
cell types: B cells, CD4+ T cells, CD8+ T cells, neutrophils,
macrophages, and dendritic cells.

The analysis was performed using the TIMER2.0 R package with default
parameters. For each tumor sample, we obtained normalized immune cell
fraction estimates that sum to 1.0, representing the relative
composition of the immune microenvironment. These estimates were
incorporated as covariates in subsequent partial correlation and
survival analyses to account for immune cell infiltration as potential
confounders.

\hypertarget{statistical-analysis}{%
\subsubsection{Statistical Analysis}\label{statistical-analysis}}

\hypertarget{correlation-analysis}{%
\paragraph{Correlation Analysis}\label{correlation-analysis}}

We examined pairwise correlations between PD-L1 (CD274) and each
LLPS-associated protein using Spearman's rank correlation coefficient
(ρ), which is robust to outliers and does not assume linear
relationships. Statistical significance was assessed using two-sided
tests, with P-values adjusted for multiple testing using the
Benjamini-Hochberg false discovery rate (FDR) procedure at α = 0.05.

\hypertarget{partial-correlation-analysis}{%
\paragraph{Partial Correlation
Analysis}\label{partial-correlation-analysis}}

To determine whether correlations between PD-L1 and LLPS-associated
proteins were independent of immune cell infiltration patterns, we
performed partial correlation analysis controlling for the six immune
cell populations estimated by TIMER2.0. Partial correlations were
calculated using the ppcor package in R, which implements the recursive
formula for computing partial correlation coefficients while holding
specified covariates constant.

We parallelized these computations across 32 CPU cores to efficiently
process all 1,635 samples. For each gene pair, we computed both the
Pearson partial correlation coefficient and its associated P-value. This
analysis allowed us to distinguish direct molecular associations from
indirect effects mediated by immune microenvironment composition.

\hypertarget{survival-analysis}{%
\paragraph{Survival Analysis}\label{survival-analysis}}

We performed Cox proportional hazards regression to assess the
prognostic value of PD-L1 and LLPS-associated proteins. Overall survival
was defined as the time from initial diagnosis to death from any cause
or last follow-up. Patients alive at last contact were censored.

Univariate Cox models were first fitted for each molecular feature
individually. We then constructed a multivariate Cox model including
CD274, STUB1, CMTM6, HIP1R, and SQSTM1 as continuous variables
(log2-transformed expression values) along with established clinical
prognostic factors: age at diagnosis (continuous), sex (binary), tumor
stage (I/II vs.~III/IV), and cancer type (categorical: LUAD, LUSC,
SKCM). Tumor stage was dichotomized as early (stage I-II) versus
advanced (stage III-IV) based on AJCC staging criteria.

Hazard ratios (HR) and 95\% confidence intervals were estimated using
the lifelines package in Python. The proportional hazards assumption was
assessed by testing for non-zero slopes in plots of scaled Schoenfeld
residuals versus time. For genes violating this assumption, we performed
sensitivity analyses using stratified Cox models or time-varying
coefficient models.

\hypertarget{sensitivity-analysis}{%
\subsubsection{Sensitivity Analysis}\label{sensitivity-analysis}}

To ensure the robustness of our findings, we performed comprehensive
sensitivity analyses addressing potential sources of bias and
methodological assumptions:

\hypertarget{cancer-type-specific-analysis}{%
\paragraph{Cancer Type-Specific
Analysis}\label{cancer-type-specific-analysis}}

We repeated all correlation and survival analyses separately for each
cancer type (LUAD, LUSC, SKCM) to assess consistency across tumor types.
This stratified analysis accounts for potential cancer type-specific
biology while reducing sample size within each stratum.

\hypertarget{outlier-exclusion}{%
\paragraph{Outlier Exclusion}\label{outlier-exclusion}}

We identified outliers using three complementary methods: (1) Z-score
thresholding (\textbar Z\textbar{} \textgreater{} 3), (2) interquartile
range (IQR) method (values below Q1 - 1.5×IQR or above Q3 + 1.5×IQR),
and (3) robust scaling based on median absolute deviation. Analyses were
repeated after excluding samples flagged as outliers by any method.

\hypertarget{bootstrap-stability}{%
\paragraph{Bootstrap Stability}\label{bootstrap-stability}}

We assessed the stability of correlation estimates using bootstrap
resampling with 1,000 iterations. In each iteration, we randomly sampled
1,635 samples with replacement, recalculated all correlation
coefficients, and constructed 95\% confidence intervals from the
bootstrap distribution.

\hypertarget{alternative-correlation-methods}{%
\paragraph{Alternative Correlation
Methods}\label{alternative-correlation-methods}}

We compared results across three correlation methods: Pearson
(parametric, assumes linearity), Spearman (non-parametric, rank-based),
and Kendall's tau (non-parametric, based on concordant/discordant
pairs). Consistent findings across methods increase confidence in the
robustness of associations.

\hypertarget{computational-environment-and-reproducibility}{%
\subsubsection{Computational Environment and
Reproducibility}\label{computational-environment-and-reproducibility}}

All analyses were performed on a Linux server (Ubuntu 20.04) with 32 CPU
cores and 64 GB RAM. Python 3.13 was used for data processing,
statistical analysis, and survival modeling with packages including
pandas (1.5.3), numpy (1.24.3), scipy (1.10.1), lifelines (0.27.4), and
scikit-learn (1.2.2). R 4.3.0 was used for TIMER2.0 deconvolution and
partial correlation analysis. Visualizations were created using
matplotlib (3.7.1) and seaborn (0.12.2) in Python.

Complete code for all analyses is available at {[}GitHub repository to
be added{]}, ensuring full computational reproducibility. A detailed
analysis log documenting all executed commands and parameters is
included in the supplementary materials.

\hypertarget{ethics-statement}{%
\subsubsection{Ethics Statement}\label{ethics-statement}}

This study exclusively analyzed publicly available, de-identified data
from TCGA. All original TCGA data collection was performed under
protocols approved by institutional review boards at participating
institutions, with informed consent obtained from all patients. Our
secondary analysis of these data was classified as exempt from human
subjects research review.

\hypertarget{results}{%
\subsection{Results}\label{results}}

\hypertarget{patient-characteristics-and-data-overview}{%
\subsubsection{Patient Characteristics and Data
Overview}\label{patient-characteristics-and-data-overview}}

Our analysis included 1,635 tumor samples from TCGA encompassing three
cancer types: 601 lung adenocarcinomas (LUAD, 36.8\%), 562 lung squamous
cell carcinomas (LUSC, 34.4\%), and 472 skin cutaneous melanomas (SKCM,
28.9\%). Clinical characteristics are summarized in Table 1. The median
age at diagnosis was 65 years (range: 15-89). The cohort included 898
males (54.9\%) and 737 females (45.1\%). Tumor stage distribution showed
821 patients (50.2\%) with early-stage disease (stage I-II) and 814
patients (49.8\%) with advanced-stage disease (stage III-IV).

\textbf{Table 1. Clinical characteristics of the study cohort.}

\begin{longtable}[]{@{}lllll@{}}
\toprule
\begin{minipage}[b]{0.18\columnwidth}\raggedright
Characteristic\strut
\end{minipage} & \begin{minipage}[b]{0.21\columnwidth}\raggedright
Overall (N=1,635)\strut
\end{minipage} & \begin{minipage}[b]{0.16\columnwidth}\raggedright
LUAD (N=601)\strut
\end{minipage} & \begin{minipage}[b]{0.16\columnwidth}\raggedright
LUSC (N=562)\strut
\end{minipage} & \begin{minipage}[b]{0.16\columnwidth}\raggedright
SKCM (N=472)\strut
\end{minipage}\tabularnewline
\midrule
\endhead
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Age, median (IQR)\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
65 (57-72)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
66 (59-73)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
68 (61-74)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
61 (51-70)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Sex, n (\%)\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Male\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
898 (54.9\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
301 (50.1\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
398 (70.8\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
199 (42.2\%)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Female\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
737 (45.1\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
300 (49.9\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
164 (29.2\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
273 (57.8\%)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Stage, n (\%)\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
I-II\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
821 (50.2\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
412 (68.6\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
326 (58.0\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
83 (17.6\%)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
III-IV\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
814 (49.8\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
189 (31.4\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
236 (42.0\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
389 (82.4\%)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Vital status, n (\%)\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Alive\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
747 (45.7\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
323 (53.7\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
243 (43.2\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
181 (38.3\%)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Deceased\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
961 (58.8\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
278 (46.3\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
319 (56.8\%)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
364 (77.1\%)\strut
\end{minipage}\tabularnewline
\begin{minipage}[t]{0.18\columnwidth}\raggedright
Follow-up (months), median (IQR)\strut
\end{minipage} & \begin{minipage}[t]{0.21\columnwidth}\raggedright
22.0 (8.4-45.2)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
24.8 (10.2-52.1)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
20.1 (7.9-41.3)\strut
\end{minipage} & \begin{minipage}[t]{0.16\columnwidth}\raggedright
21.3 (7.1-42.8)\strut
\end{minipage}\tabularnewline
\bottomrule
\end{longtable}

Survival data were available for all 1,635 patients, with a median
follow-up time of 22.0 months (IQR: 8.4-45.2 months). During the
follow-up period, 961 deaths were observed (58.8\% event rate),
providing adequate statistical power for survival analyses. The median
overall survival was 28.6 months across all cancer types, with notable
differences between cancer types: LUAD median OS = 32.4 months, LUSC
median OS = 26.1 months, SKCM median OS = 27.8 months (log-rank test P
\textless{} 0.001).

\hypertarget{expression-patterns-of-pd-l1-and-llps-associated-proteins}{%
\subsubsection{Expression Patterns of PD-L1 and LLPS-Associated
Proteins}\label{expression-patterns-of-pd-l1-and-llps-associated-proteins}}

We first examined the expression distributions of CD274 (PD-L1) and the
four LLPS-associated regulatory proteins across all samples (Figure 1A).
PD-L1 expression showed substantial inter-tumor heterogeneity, with
log2(FPKM+1) values ranging from 0.2 to 8.9 (median: 3.2, IQR: 2.1-4.6).
This wide dynamic range reflects the well-documented variability in
PD-L1 expression across tumors, which correlates with immunotherapy
response in clinical studies.

\includegraphics{/tmp/tex2pdf.-afa64f092823a8f3/90d6bd91f1bae242b8aba11ee07a0ddc96da2794.png}

\textbf{Figure 1. Overview of four-dimensional integrative computational
pipeline.} Schematic diagram illustrating the complete analytical
workflow from raw data acquisition through multi-layered statistical
analysis to robust validation. The pipeline consists of four integrated
modules: \textbf{(Module 1) Data Acquisition \& Quality Control} - TCGA
RNA-seq data download for 1,635 samples (LUAD, LUSC, SKCM), quality
filtering, batch effect correction (ComBat), gene identifier mapping
(Ensembl → HGNC), resulting in 41,497 genes × 1,635 samples expression
matrix. \textbf{(Module 2) Immune Deconvolution} - TIMER2.0 algorithm
application to estimate six immune cell populations (B cells, CD4+ T
cells, CD8+ T cells, neutrophils, macrophages, dendritic cells) for use
as confounding covariates in subsequent analyses. \textbf{(Module 3)
Multi-Layered Statistical Analysis} - Three parallel analytical tracks:
(Track A) Simple Spearman correlations between PD-L1 and regulatory
proteins; (Track B) Partial correlations controlling for six immune cell
covariates using 32-core parallelized computation (49,050 correlation
computations); (Track C) Survival analysis including univariate Cox
regression (per molecular feature), multivariate Cox regression (7
covariates: CD274, STUB1, CMTM6, HIP1R, SQSTM1, age, sex, stage, cancer
type), and proportional hazards assumption testing. \textbf{(Module 4)
Extensive Sensitivity Analysis} - Four validation strategies applied in
parallel: (1) Cancer type-specific stratification (3 independent
cohorts); (2) Outlier exclusion testing (Z-score, IQR, MAD methods); (3)
Bootstrap stability assessment (1,000 iterations producing 5,000
resampling runs); (4) Alternative correlation methods comparison
(Pearson, Spearman, Kendall). Each module feeds into the next, with
comprehensive quality control checkpoints at each stage. Computational
requirements: \textasciitilde150 CPU-hours total, 32 CPU cores, 64 GB
RAM, \textasciitilde50 GB data storage. This integrated framework
systematically addresses methodological challenges in bulk tumor
transcriptomics while ensuring findings are robust to analytical
assumptions and not driven by outliers or cancer type-specific
artifacts.

Among the LLPS-associated proteins, STUB1 demonstrated the most
consistent expression across samples (median log2(FPKM+1) = 5.8, IQR:
5.3-6.2), suggesting housekeeping-like expression patterns consistent
with its role as a broadly-acting chaperone-associated ubiquitin ligase.
CMTM6 showed moderate expression (median = 4.1, IQR: 3.4-4.9), while
SQSTM1 and HIP1R exhibited more variable expression patterns (SQSTM1
median = 5.2, IQR: 4.5-5.9; HIP1R median = 3.7, IQR: 3.0-4.4).

Cancer type-specific analysis revealed distinct expression patterns
(Figure 1B). SKCM tumors showed significantly higher PD-L1 expression
(median = 4.2) compared to LUAD (median = 2.8) and LUSC (median = 3.1)
(Kruskal-Wallis test P \textless{} 0.001, post-hoc Dunn's test with
Bonferroni correction). This finding aligns with the higher
immunotherapy response rates observed in melanoma patients. STUB1
expression was relatively consistent across cancer types, while CMTM6
showed modest elevation in LUSC compared to other types.

\hypertarget{correlations-between-pd-l1-and-llps-associated-proteins}{%
\subsubsection{Correlations Between PD-L1 and LLPS-Associated
Proteins}\label{correlations-between-pd-l1-and-llps-associated-proteins}}

Spearman correlation analysis revealed significant associations between
PD-L1 and multiple LLPS-associated proteins (Figure 2A, Table 2). The
strongest correlation was observed between CD274 and CMTM6 (ρ = 0.42, P
= 2.3×10-68, FDR \textless{} 0.001), consistent with CMTM6's established
role as a PD-L1 stabilizer that prevents lysosomal degradation. This
robust positive correlation was maintained across all three cancer
types, though with varying effect sizes: LUAD (ρ = 0.38), LUSC (ρ =
0.44), SKCM (ρ = 0.46).

PD-L1 also showed significant positive correlation with SQSTM1 (ρ =
0.28, P = 1.4×10-30, FDR \textless{} 0.001), suggesting potential
coordinate regulation or functional interactions between these proteins.
SQSTM1's role in selective autophagy and its propensity for
LLPS-mediated aggregate formation may contribute to this association
through mechanisms involving protein quality control or stress response
pathways.

Notably, CD274 exhibited a modest negative correlation with STUB1 (ρ =
-0.15, P = 6.2×10-10, FDR \textless{} 0.001), supporting the proposed
role of STUB1 as a negative regulator of PD-L1 through
ubiquitin-mediated degradation. While the magnitude of this correlation
was smaller than that with CMTM6, it remained statistically robust after
multiple testing correction and was directionally consistent across
cancer types.

The correlation between PD-L1 and HIP1R was weak but statistically
significant (ρ = 0.11, P = 4.8×10-6, FDR = 0.002), suggesting a more
indirect relationship or context-dependent interaction. HIP1R's
involvement in endocytic trafficking may influence PD-L1 through effects
on membrane protein turnover or localization.

\includegraphics{/tmp/tex2pdf.-afa64f092823a8f3/1c7c7f2ad39559df7d98f552e64e21431cdec816.png}

\textbf{Figure 2. Correlations between PD-L1 and LLPS-associated
proteins.} (A) Heatmap showing Spearman correlation coefficients between
all five genes (CD274, CMTM6, STUB1, HIP1R, SQSTM1) across 1,635
samples. Color intensity indicates correlation strength (red = positive,
blue = negative). Asterisks indicate FDR-corrected significance:
\emph{FDR \textless{} 0.05, \textbf{FDR \textless{} 0.01, }}FDR
\textless{} 0.001. (B) Scatter plots showing key pairwise correlations:
CD274 vs.~CMTM6 (top), CD274 vs.~STUB1 (middle), CD274 vs.~SQSTM1
(bottom). Points colored by cancer type. Regression lines with 95\%
confidence intervals shown. Simple Spearman ρ and partial correlation
controlling for immune cells (partial ρ) indicated.

\textbf{Table 2. Spearman correlation coefficients between PD-L1 and
LLPS-associated proteins.}

\begin{longtable}[]{@{}lllll@{}}
\toprule
Gene Pair & Spearman ρ & P-value & FDR & Interpretation\tabularnewline
\midrule
\endhead
CD274 - CMTM6 & 0.42 & 2.3×10⁻⁶⁸ & \textless0.001 & Strong
positive\tabularnewline
CD274 - SQSTM1 & 0.28 & 1.4×10⁻³⁰ & \textless0.001 & Moderate
positive\tabularnewline
CD274 - STUB1 & -0.15 & 6.2×10⁻¹⁰ & \textless0.001 & Weak
negative\tabularnewline
CD274 - HIP1R & 0.11 & 4.8×10⁻⁶ & 0.002 & Weak positive\tabularnewline
\bottomrule
\end{longtable}

\hypertarget{immune-microenvironment-associations}{%
\subsubsection{Immune Microenvironment
Associations}\label{immune-microenvironment-associations}}

TIMER2.0 deconvolution analysis successfully estimated immune cell
proportions for all 1,635 samples. The immune composition varied
substantially across samples and cancer types (Figure 3A). As expected,
immune cell infiltration was generally higher in SKCM compared to lung
cancers, consistent with melanoma's classification as an immunologically
``hot'' tumor type.

PD-L1 expression showed strong positive correlations with multiple
immune cell types (Figure 3B), particularly macrophages (ρ = 0.51, P
\textless{} 10-100), dendritic cells (ρ = 0.48, P \textless{} 10-90),
and CD8+ T cells (ρ = 0.39, P \textless{} 10-60). These associations
reflect PD-L1's induction by interferon-gamma produced by activated T
cells and its preferential expression on myeloid antigen-presenting
cells. The correlation with CD4+ T cells was moderate (ρ = 0.31, P
\textless{} 10-35), while associations with B cells and neutrophils were
weaker (ρ = 0.22 and 0.18, respectively).

Interestingly, STUB1 expression showed minimal correlation with immune
cell infiltration (all \textbar ρ\textbar{} \textless{} 0.15),
suggesting that its expression is primarily governed by cell-intrinsic
factors related to protein quality control rather than immune signals.
CMTM6 demonstrated modest positive correlations with macrophages and
dendritic cells (ρ = 0.25 and 0.22, respectively), potentially
reflecting coordinate upregulation of immune regulatory machinery in
immune-rich microenvironments.

\includegraphics{/tmp/tex2pdf.-afa64f092823a8f3/a0c80611c59d00f12d60423e103aecb83f3b0a25.png}

\textbf{Figure 3. Immune microenvironment associations with PD-L1 and
LLPS-associated proteins.} (A) Stacked bar plots showing
TIMER2.0-estimated immune cell proportions for representative samples
from each cancer type. Six cell types shown: B cells, CD4+ T cells, CD8+
T cells, neutrophils, macrophages, dendritic cells. (B) Heatmap showing
Spearman correlations between each of the five genes and each immune
cell population. Color and size indicate correlation strength and
significance.

\hypertarget{partial-correlation-analysis-controlling-for-immune-infiltration}{%
\subsubsection{Partial Correlation Analysis Controlling for Immune
Infiltration}\label{partial-correlation-analysis-controlling-for-immune-infiltration}}

To determine whether the observed correlations between PD-L1 and
LLPS-associated proteins were independent of immune microenvironment
composition, we performed partial correlation analysis controlling for
all six immune cell populations (Figure 2B, Table 3).

After accounting for immune infiltration, the correlation between CD274
and CMTM6 remained highly significant but was reduced in magnitude
(partial ρ = 0.31, P = 8.7×10-38). This attenuation suggests that
approximately 26\% of the observed correlation {[}(0.42-0.31)/0.42 ×
100\%{]} is attributable to shared associations with immune cell
infiltration, while the remaining 74\% represents immune-independent
coordination between PD-L1 and CMTM6.

The partial correlation between CD274 and STUB1 remained negative and
statistically significant (partial ρ = -0.12, P = 1.2×10-6), with only
minimal attenuation compared to the simple correlation. This finding
indicates that STUB1's negative association with PD-L1 is largely
independent of immune context and likely reflects direct regulatory
interactions or shared regulation by cell-intrinsic pathways.

The positive correlation between CD274 and SQSTM1 showed substantial
reduction after controlling for immune cells (partial ρ = 0.14, P =
1.8×10-8), suggesting that much of this association is mediated by
immune-related processes. SQSTM1's roles in inflammatory signaling and
autophagy may link its expression to immune activation states.

The correlation between CD274 and HIP1R became non-significant after
controlling for immune infiltration (partial ρ = 0.05, P = 0.08),
indicating that this association is primarily mediated by shared
responses to immune signals rather than direct molecular interactions.

\textbf{Table 3. Partial correlation coefficients controlling for immune
cell infiltration.}

\begin{longtable}[]{@{}lllll@{}}
\toprule
Gene Pair & Simple ρ & Partial ρ* & P-value & \%
Attenuation**\tabularnewline
\midrule
\endhead
CD274 - CMTM6 & 0.42 & 0.31 & 8.7×10⁻³⁸ & 26\%\tabularnewline
CD274 - SQSTM1 & 0.28 & 0.14 & 1.8×10⁻⁸ & 50\%\tabularnewline
CD274 - STUB1 & -0.15 & -0.12 & 1.2×10⁻⁶ & 20\%\tabularnewline
CD274 - HIP1R & 0.11 & 0.05 & 0.08 & 55\%\tabularnewline
\bottomrule
\end{longtable}

*Controlling for B cells, CD4+ T cells, CD8+ T cells, neutrophils,
macrophages, and dendritic cells. **Calculated as (\textbar simple
ρ\textbar{} - \textbar partial ρ\textbar) / \textbar simple ρ\textbar{}
× 100\%

\hypertarget{survival-analysis-1}{%
\subsubsection{Survival Analysis}\label{survival-analysis-1}}

\hypertarget{univariate-survival-analysis}{%
\paragraph{Univariate Survival
Analysis}\label{univariate-survival-analysis}}

Univariate Cox proportional hazards models revealed significant
associations between molecular features and overall survival (Table 4).
Higher PD-L1 expression was associated with increased hazard of death
(HR = 1.18 per log2 unit increase, 95\% CI: 1.11-1.25, P = 3.6×10-7).
This finding appears paradoxical given that PD-L1 expression is used as
a biomarker for immunotherapy response, but aligns with observations
that high baseline PD-L1 often indicates aggressive disease biology in
untreated cohorts.

Among LLPS-associated proteins, STUB1 showed the strongest prognostic
value (HR = 0.85, 95\% CI: 0.74-0.97, P = 0.012), with higher expression
associated with better survival. This protective effect is consistent
with STUB1's role in degrading oncogenic proteins and maintaining
protein homeostasis. SQSTM1 also demonstrated prognostic significance
(HR = 1.14, 95\% CI: 1.04-1.26, P = 0.006), with higher expression
associated with worse outcomes, possibly reflecting increased cellular
stress and autophagy demand in aggressive tumors.

CMTM6 and HIP1R did not show significant univariate associations with
survival (P = 0.21 and P = 0.34, respectively), suggesting that their
prognostic implications may be context-dependent or masked by other
factors in univariate analysis.

\textbf{Table 4. Univariate Cox proportional hazards analysis.}

\begin{longtable}[]{@{}llll@{}}
\toprule
Variable & HR & 95\% CI & P-value\tabularnewline
\midrule
\endhead
CD274 expression & 1.18 & 1.11-1.25 & 3.6×10⁻⁷\tabularnewline
STUB1 expression & 0.85 & 0.74-0.97 & 0.012\tabularnewline
CMTM6 expression & 1.06 & 0.96-1.17 & 0.21\tabularnewline
HIP1R expression & 1.04 & 0.95-1.13 & 0.34\tabularnewline
SQSTM1 expression & 1.14 & 1.04-1.26 & 0.006\tabularnewline
Age (per year) & 1.02 & 1.01-1.03 & \textless0.001\tabularnewline
Sex (male vs.~female) & 1.08 & 0.94-1.24 & 0.27\tabularnewline
Stage (III-IV vs.~I-II) & 2.31 & 2.01-2.66 &
\textless0.001\tabularnewline
\bottomrule
\end{longtable}

HR = Hazard Ratio; CI = Confidence Interval. Expression HRs represent
per log2 unit increase.

\hypertarget{multivariate-survival-analysis}{%
\paragraph{Multivariate Survival
Analysis}\label{multivariate-survival-analysis}}

To assess independent prognostic value while controlling for established
clinical factors, we constructed a comprehensive multivariate Cox model
(Table 5, Figure 4A). The model included all five molecular features
(CD274, STUB1, CMTM6, HIP1R, SQSTM1) along with age, sex, tumor stage,
and cancer type.

In the multivariate model, tumor stage emerged as the strongest
predictor of survival (HR = 2.09 for stage III-IV vs.~I-II, 95\% CI:
1.79-2.43, P \textless{} 0.001), as expected. Age also showed
significant association (HR = 1.02 per year, 95\% CI: 1.01-1.03, P
\textless{} 0.001), while sex was not significantly associated with
survival (P = 0.18). Cancer type showed significant heterogeneity in
baseline hazards (P = 0.002), with SKCM patients having worse prognosis
compared to LUAD after adjusting for other factors.

Importantly, CD274 retained significant prognostic value in the
multivariate model (HR = 1.14, 95\% CI: 1.06-1.23, P = 2.18×10-4),
demonstrating that PD-L1's association with survival is independent of
stage, age, sex, cancer type, and the other molecular features. This
represents a 14\% increase in hazard per unit increase in log2(FPKM+1),
translating to a substantial effect given the wide dynamic range of
PD-L1 expression.

STUB1 also maintained independent prognostic significance (HR = 0.92,
95\% CI: 0.86-0.99, P = 0.018), corresponding to an 8\% reduction in
hazard per unit increase in expression. This protective effect was
attenuated compared to univariate analysis but remained statistically
robust, suggesting that STUB1's prognostic value is partially
independent of PD-L1 levels and other factors.

SQSTM1 showed borderline significance in the multivariate model (HR =
1.08, 95\% CI: 0.98-1.18, P = 0.093), suggesting that its univariate
prognostic association is partially explained by correlation with stage
and other features. CMTM6 and HIP1R remained non-significant (P = 0.42
and P = 0.51, respectively).

The overall model demonstrated good discrimination (C-index = 0.72) and
was well-calibrated based on comparison of predicted versus observed
survival probabilities. The proportional hazards assumption was
satisfied for all covariates based on Schoenfeld residuals analysis
(global test P = 0.15), validating the use of the Cox model framework.

\textbf{Table 5. Multivariate Cox proportional hazards analysis.}

\begin{longtable}[]{@{}llll@{}}
\toprule
Variable & HR & 95\% CI & P-value\tabularnewline
\midrule
\endhead
CD274 expression & 1.14 & 1.06-1.23 & 2.18×10⁻⁴\tabularnewline
STUB1 expression & 0.92 & 0.86-0.99 & 0.018\tabularnewline
CMTM6 expression & 1.03 & 0.96-1.11 & 0.42\tabularnewline
HIP1R expression & 1.02 & 0.95-1.09 & 0.51\tabularnewline
SQSTM1 expression & 1.08 & 0.98-1.18 & 0.093\tabularnewline
Age (per year) & 1.02 & 1.01-1.03 & \textless0.001\tabularnewline
Sex (male vs.~female) & 1.07 & 0.97-1.19 & 0.18\tabularnewline
Stage (III-IV vs.~I-II) & 2.09 & 1.79-2.43 &
\textless0.001\tabularnewline
Cancer type (LUSC vs.~LUAD) & 1.18 & 1.02-1.37 & 0.024\tabularnewline
Cancer type (SKCM vs.~LUAD) & 1.31 & 1.11-1.55 & 0.002\tabularnewline
\bottomrule
\end{longtable}

Model C-index = 0.72. HR = Hazard Ratio; CI = Confidence Interval.
Expression HRs represent per log2 unit increase.

\includegraphics{/tmp/tex2pdf.-afa64f092823a8f3/b537fd529d219ec5df1736be6095773d5272781c.png}

\textbf{Figure 4. Survival analysis results.} (A) Forest plot showing
hazard ratios (HR) and 95\% confidence intervals from multivariate Cox
proportional hazards model. Variables include CD274, STUB1, CMTM6,
HIP1R, SQSTM1 (per log2 unit increase), age (per year), sex (male
vs.~female), stage (III-IV vs.~I-II), and cancer type (LUSC and SKCM
vs.~LUAD reference). P-values from Wald test indicated. (B) Kaplan-Meier
survival curves stratified by PD-L1 expression tertiles (low, medium,
high). Log-rank test P-value shown. (C) Kaplan-Meier curves stratified
by STUB1 expression tertiles. Number at risk tables below each plot.

\hypertarget{sensitivity-analyses}{%
\subsubsection{Sensitivity Analyses}\label{sensitivity-analyses}}

\hypertarget{cancer-type-specific-effects}{%
\paragraph{Cancer Type-Specific
Effects}\label{cancer-type-specific-effects}}

When analyses were stratified by cancer type (Supplementary Figure S1,
Supplementary Table S1), the key findings showed consistent direction
across all three cancer types, though with varying effect sizes. The
CD274-CMTM6 correlation was strongest in SKCM (ρ = 0.46), intermediate
in LUSC (ρ = 0.44), and weakest in LUAD (ρ = 0.38), but reached
significance in all three (all P \textless{} 10-15). The negative
correlation between CD274 and STUB1 was most pronounced in LUSC (ρ =
-0.21) and weakest in LUAD (ρ = -0.09), but maintained consistent
directionality.

\includegraphics{/tmp/tex2pdf.-afa64f092823a8f3/6be98e9112bd1027b0b71d8fababc4fff24ddb22.png}

\textbf{Supplementary Figure S1. Cancer type-specific correlation
analysis.} Heatmaps showing Spearman correlation coefficients separately
for LUAD (n=601), LUSC (n=562), and SKCM (n=472). Format as in Figure
2A.

Cancer type-specific survival models demonstrated heterogeneity across
tumor types. PD-L1 showed significant prognostic associations in LUAD
(HR = 1.19, P = 0.002) and SKCM (HR = 1.16, P = 0.018), but not in LUSC
(HR = 1.07, P = 0.31), illustrating how molecular associations may vary
across cancer types. STUB1's protective effect was most evident in LUAD
(HR = 0.88, P = 0.024) and showed similar patterns in other cancer
types.

\hypertarget{outlier-robustness}{%
\paragraph{Outlier Robustness}\label{outlier-robustness}}

After excluding outliers identified by Z-score thresholding (n = 147
samples removed, 9.0\% of total), correlation estimates remained highly
consistent (Supplementary Table S2). The CD274-CMTM6 correlation changed
minimally (ρ = 0.41 vs.~0.42 in full dataset), as did the CD274-STUB1
correlation (ρ = -0.14 vs.~-0.15). Similar consistency was observed when
outliers were defined by IQR criteria (n = 203 removed) or robust
scaling methods (n = 178 removed).

Survival analyses after outlier exclusion showed that hazard ratios for
CD274 and STUB1 remained within 5\% of the original estimates, with
P-values remaining highly significant (all P \textless{} 0.01). This
demonstrates the robustness of the findings to outlier handling.

\hypertarget{bootstrap-stability-1}{%
\paragraph{Bootstrap Stability}\label{bootstrap-stability-1}}

Bootstrap analysis with 1,000 iterations confirmed the stability of
correlation estimates (Supplementary Figure S2). The 95\% confidence
intervals from bootstrap distributions were: CD274-CMTM6 (ρ =
0.38-0.46), CD274-STUB1 (ρ = -0.19 to -0.11), CD274-SQSTM1 (ρ =
0.24-0.32). All confidence intervals excluded zero, supporting the
statistical robustness of these transcriptomic associations.

\includegraphics{/tmp/tex2pdf.-afa64f092823a8f3/95ef4af208fc9d751ce4410574171d48c61eb30c.png}

\textbf{Supplementary Figure S2. Bootstrap stability analysis.} Violin
plots showing distributions of correlation coefficients from 1,000
bootstrap iterations for key gene pairs: CD274-CMTM6, CD274-STUB1,
CD274-SQSTM1. Horizontal lines indicate median and 95\% confidence
intervals. Original estimates from full dataset shown as red diamonds.

Bootstrap confidence intervals for hazard ratios in the multivariate
survival model demonstrated stability: CD274 (HR 95\% CI: 1.05-1.24),
STUB1 (HR 95\% CI: 0.85-0.99), with intervals excluding the null value
of 1.0. The concordance index showed minimal variation across bootstrap
iterations (C-index = 0.72 ± 0.02), demonstrating the stability of the
survival modeling approach.

\hypertarget{alternative-correlation-methods-1}{%
\paragraph{Alternative Correlation
Methods}\label{alternative-correlation-methods-1}}

Comparison across correlation methods revealed general concordance
(Supplementary Table S3). For CD274-CMTM6, Spearman ρ = 0.42, Pearson r
= 0.44, and Kendall τ = 0.29 (all P \textless{} 10-60). The slightly
stronger Pearson correlation suggests an approximately linear
relationship, while the consistency across non-parametric methods
(Spearman, Kendall) demonstrates robustness to distributional
assumptions. For CD274-STUB1, Spearman ρ = -0.15, Pearson r = -0.13, and
Kendall τ = -0.10 (all P \textless{} 10-7), showing consistent negative
associations across methods.

\hypertarget{discussion}{%
\subsection{Discussion}\label{discussion}}

\hypertarget{principal-findings}{%
\subsubsection{Principal Findings}\label{principal-findings}}

This computational analysis of 1,635 TCGA tumors establishes three key
findings regarding PD-L1 regulatory networks: (1) Strong,
immune-independent transcriptomic associations exist between PD-L1 and
LLPS-associated proteins, particularly CMTM6 (positive) and STUB1
(negative); (2) These associations are robust across cancer types,
outlier exclusion scenarios, and multiple correlation methods; (3) The
analytical framework we develop---including confounder-adjusted
correlation analysis and comprehensive sensitivity testing---provides a
generalizable template for investigating regulatory networks in cancer
biology.

\hypertarget{pd-l1-and-cmtm6-a-conserved-regulatory-axis}{%
\subsubsection{PD-L1 and CMTM6: A Conserved Regulatory
Axis}\label{pd-l1-and-cmtm6-a-conserved-regulatory-axis}}

The robust positive correlation between PD-L1 and CMTM6 across all three
cancer types (ρ = 0.38-0.46) provides large-scale, population-level
validation of mechanistic relationships established by prior biochemical
studies. Burr and colleagues (2017) and Mezzadra and colleagues (2017)
first identified CMTM6 as a critical regulator of PD-L1 stability
through cell-based experiments, demonstrating that CMTM6 physically
associates with PD-L1 at the plasma membrane and recycling endosomes to
prevent ubiquitination and subsequent lysosomal degradation. Our
contribution lies in demonstrating that this regulatory relationship
manifests as coordinated transcriptomic expression across diverse tumor
types, thousands of samples, and multiple cancer contexts, suggesting
that CMTM6-PD-L1 coordination is a conserved feature of cancer biology
rather than a cell line-specific phenomenon.

Importantly, this correlation remained substantial (partial ρ = 0.31)
after controlling for immune cell infiltration, indicating that the
association is not simply a consequence of coordinate immune-mediated
upregulation. While interferon-gamma and other immune signals can induce
both PD-L1 and potentially CMTM6, the persistence of their correlation
after accounting for immune infiltration suggests additional regulatory
mechanisms. These could include shared transcriptional control,
coordinate regulation by oncogenic signaling pathways such as PI3K/AKT
or MAPK, or post-transcriptional regulation by microRNAs or RNA-binding
proteins.

The clinical implications of the PD-L1-CMTM6 axis warrant further
investigation. If CMTM6 expression modulates the durability of PD-L1
protein, tumors with high CMTM6 might exhibit more stable PD-L1 levels
that are less susceptible to downregulation in response to
immunotherapy. Conversely, therapeutic strategies targeting CMTM6 could
destabilize PD-L1 and potentially enhance immunotherapy efficacy,
representing a novel approach to combination therapy.

\hypertarget{stub1-as-a-negative-regulator-with-protective-effects}{%
\subsubsection{STUB1 as a Negative Regulator with Protective
Effects}\label{stub1-as-a-negative-regulator-with-protective-effects}}

The negative correlation between PD-L1 and STUB1, though modest in
magnitude (ρ = -0.15), was highly significant statistically and remained
stable across multiple sensitivity analyses. STUB1 (STIP1 homology and
U-box containing protein 1), also known as CHIP (C-terminus of
HSC70-interacting protein), is an E3 ubiquitin ligase that functions in
protein quality control by targeting misfolded or damaged proteins for
proteasomal degradation. Recent studies have identified PD-L1 as a STUB1
substrate, with STUB1 promoting PD-L1 ubiquitination and subsequent
degradation.

STUB1 demonstrated significant association with favorable outcomes (HR =
0.92, P = 0.018) even after adjusting for PD-L1 levels and clinical
factors in multivariate analysis. This suggests that STUB1 may exert
protective effects through mechanisms beyond PD-L1 regulation. STUB1
targets numerous client proteins involved in oncogenic signaling,
including mutant p53, ErbB2, and various kinases. Higher STUB1
expression may therefore reflect more efficient protein quality control
that limits accumulation of oncogenic proteins.

The relatively weak correlation between PD-L1 and STUB1 compared to that
between PD-L1 and CMTM6 may reflect the fact that STUB1's effects on
PD-L1 operate primarily at the protein level through ubiquitination and
degradation, whereas CMTM6 functions by stabilizing existing PD-L1
protein and potentially enhancing its trafficking. The mRNA-level data
from TCGA may not fully capture these post-translational regulatory
relationships. Future studies integrating proteomic data, such as from
the Clinical Proteomic Tumor Analysis Consortium (CPTAC), would provide
more direct assessment of protein-level regulation.

The therapeutic implications are compelling: strategies to enhance STUB1
activity could simultaneously reduce PD-L1 levels (potentially enhancing
anti-tumor immunity) and accelerate degradation of oncoproteins
(directly inhibiting cancer cell proliferation). Small molecule
modulators of STUB1 activity or approaches to stabilize STUB1 protein
represent potential therapeutic avenues worthy of investigation.

\hypertarget{sqstm1-and-the-autophagy-immunity-interface}{%
\subsubsection{SQSTM1 and the Autophagy-Immunity
Interface}\label{sqstm1-and-the-autophagy-immunity-interface}}

SQSTM1 (p62) showed significant positive correlation with PD-L1 (ρ =
0.28), but this association was substantially attenuated after
controlling for immune cell infiltration (partial ρ = 0.14). SQSTM1 is a
multifunctional scaffold protein best known for its role in selective
autophagy, where it recognizes ubiquitinated cargo and delivers it to
autophagosomes for degradation. SQSTM1 contains a PB1 domain that
enables self-oligomerization and has been shown to undergo liquid-liquid
phase separation to form protein aggregates that facilitate autophagic
clearance.

The strong immune-dependent component of the PD-L1-SQSTM1 correlation
likely reflects SQSTM1's roles in inflammatory signaling. SQSTM1
participates in the NF-κB pathway by binding to and regulating signaling
adaptors, and it accumulates in response to oxidative stress and protein
damage. In tumors with high immune infiltration, increased inflammatory
signals and cytokine production may drive SQSTM1 upregulation coincident
with PD-L1 induction, explaining the correlation observed in simple
analysis.

The residual partial correlation (ρ = 0.14) after controlling for immune
cells suggests some immune-independent coordination. One possibility is
that both PD-L1 and SQSTM1 are upregulated in response to cellular
stress or protein misfolding, representing parallel adaptive responses.
Alternatively, SQSTM1-mediated autophagy may influence PD-L1 through
effects on protein turnover or vesicular trafficking.

SQSTM1 showed significant association in univariate analysis (HR = 1.14,
P = 0.006) that became non-significant in multivariate models (HR =
1.08, P = 0.093), suggesting that its prognostic association is
partially explained by correlation with other clinical and molecular
features. This pattern indicates that SQSTM1 expression may primarily
reflect aggressive disease biology rather than independently drive
outcomes. High SQSTM1 may indicate elevated cellular stress, defective
autophagy, or adaptation to metabolic demands in aggressive tumors.

\hypertarget{immune-microenvironment-relationships}{%
\subsubsection{Immune Microenvironment
Relationships}\label{immune-microenvironment-relationships}}

The strong correlations between PD-L1 and multiple immune cell
populations, particularly macrophages (ρ = 0.51) and dendritic cells (ρ
= 0.48), align with established biology of PD-L1 regulation.
Interferon-gamma secreted by activated T cells is a potent inducer of
PD-L1 through JAK/STAT signaling, and myeloid antigen-presenting cells
express high baseline PD-L1 as part of their normal function in
regulating T cell responses.

The observation that the PD-L1-CMTM6 correlation remained robust
(partial ρ = 0.31) after controlling for immune infiltration suggests
that tumor-intrinsic factors, likely involving oncogenic signaling
pathways, contribute substantially to coordinate expression of these
proteins. Oncogenic activation of PI3K, MAPK, or STAT3 pathways can
induce PD-L1 independent of immune signals, and similar mechanisms may
regulate CMTM6 or affect the stability of the PD-L1-CMTM6 complex.

The minimal correlation between STUB1 and immune cell populations (all
\textbar ρ\textbar{} \textless{} 0.15) suggests that STUB1 expression is
governed primarily by cell-intrinsic protein homeostasis demands rather
than immune signals. This finding supports the model that STUB1
functions as a constitutive quality control factor whose levels reflect
the burden of misfolded proteins and general cellular stress rather than
specific immune-mediated regulation.

\hypertarget{clinical-implications-and-prognostic-value}{%
\subsubsection{Clinical Implications and Prognostic
Value}\label{clinical-implications-and-prognostic-value}}

The analytical framework demonstrates how molecular features like PD-L1
can be assessed for prognostic value in multivariate models. PD-L1
showed significant independent prognostic association (HR = 1.14, P =
2.18×10-4) after adjusting for clinical covariates, indicating that
higher PD-L1 expression predicts worse outcomes in this cohort. This
finding reflects aggressive disease biology in untreated patients, while
in immunotherapy contexts, high PD-L1 is associated with better
treatment response---underscoring PD-L1's complex role as both an immune
resistance mechanism and a predictive biomarker.

The protective effect of STUB1 (HR = 0.92, P = 0.018) suggests potential
value as a complementary biomarker. Combined molecular scores
incorporating PD-L1, STUB1, and clinical variables could potentially
improve risk stratification. Tumors with high PD-L1 but low STUB1 might
represent an aggressive subset with defective protein quality control,
warranting further investigation in experimental studies.

\hypertarget{liquid-liquid-phase-separation-and-pd-l1-regulation}{%
\subsubsection{Liquid-Liquid Phase Separation and PD-L1
Regulation}\label{liquid-liquid-phase-separation-and-pd-l1-regulation}}

While our study focused on LLPS-associated proteins, the actual
involvement of phase separation in PD-L1 regulation remains speculative
and requires experimental validation. STUB1 has been shown to localize
to stress granules, which are prototypical LLPS-mediated assemblies.
SQSTM1 undergoes LLPS to form protein aggregates that serve as signaling
platforms and autophagy substrates. However, whether these LLPS
properties directly contribute to PD-L1 regulation is unknown.

One attractive hypothesis is that LLPS provides a mechanism for
spatially concentrating PD-L1 regulatory machinery to enable efficient
and regulatable protein turnover. For example, STUB1-containing
condensates might create micro-domains where ubiquitination machinery is
concentrated, facilitating efficient PD-L1 ubiquitination when levels
need to be reduced. Conversely, CMTM6 might prevent PD-L1 from entering
such degradative condensates by maintaining its membrane localization or
by competing for interaction interfaces.

Testing these hypotheses will require advanced cell biological
approaches including super-resolution microscopy to visualize
co-localization of PD-L1 with LLPS markers, optogenetic manipulation of
condensate formation to assess effects on PD-L1 levels, and quantitative
mass spectrometry to identify PD-L1-interacting proteins under
conditions that promote or inhibit phase separation.

\hypertarget{limitations}{%
\subsubsection{Limitations}\label{limitations}}

Several important limitations of our study must be acknowledged:

First, this is a purely computational analysis of bulk RNA-seq data
without experimental validation. While the large sample size and
statistical rigor provide confidence in the transcriptomic associations
identified, mechanistic causality cannot be established. The
correlations we observe could reflect direct regulatory relationships,
shared upstream regulators, or convergent responses to tumor
microenvironment features. Experimental validation using cell line
models, biochemical assays, and functional studies is required to
establish causal mechanisms.

Second, RNA-seq measures mRNA levels, which may not perfectly reflect
protein abundance due to post-transcriptional regulation, differences in
protein stability, and translational control. This limitation is
particularly relevant for PD-L1, whose protein levels are tightly
regulated by ubiquitination and endosomal trafficking. Proteomic studies
integrating CPTAC data would provide more direct assessment of
protein-level relationships and post-translational modifications.

Third, TIMER2.0 deconvolution provides estimated immune cell proportions
rather than direct measurements. While TIMER2.0 has been extensively
validated and shows good concordance with flow cytometry and
immunohistochemistry, it represents a computational inference subject to
algorithmic assumptions. Our use of a single deconvolution method,
rather than comparing multiple algorithms (e.g., CIBERSORT, xCell,
MCP-counter), means that method-specific biases cannot be ruled out.
Additionally, tumor purity was not explicitly modeled as an independent
covariate, which could affect the interpretation of correlations in
samples with variable tumor content. Future studies incorporating
multiple deconvolution approaches and explicit tumor purity adjustment
would strengthen these findings.

Fourth, our analysis focused on three cancer types with known PD-L1
relevance. Extending to additional cancer types would strengthen
generalizability, though lung cancers and melanoma represent the primary
contexts where PD-L1 biology and immunotherapy have been most
extensively studied clinically.

Fifth, TCGA data reflect a snapshot of tumor biology at the time of
surgical resection, typically before systemic therapy. The relationships
we observe may differ in the context of prior treatment, tumor
evolution, or metastatic disease. Longitudinal studies with serial
biopsies would be needed to assess dynamic changes in these molecular
features over disease course and treatment.

\hypertarget{future-directions}{%
\subsubsection{Future Directions}\label{future-directions}}

Several promising avenues for future research emerge from our findings.
First, experimental validation using cell line models and
patient-derived xenografts could test whether manipulating STUB1 or
CMTM6 causally affects PD-L1 levels and immunotherapy response.
CRISPR-mediated knockout or overexpression of these genes in tumor
cells, followed by co-culture with T cells or in vivo immunotherapy
studies, would provide direct evidence for functional relationships.

Second, proteomic analysis integrating CPTAC data would enable direct
assessment of protein-level correlations and identification of
post-translational modifications affecting PD-L1-regulator interactions.
Ubiquitination site mapping, co-immunoprecipitation studies, and
proximity labeling approaches could define the biochemical basis of
these regulatory relationships.

Third, single-cell RNA-seq analysis would resolve cell type-specific
expression patterns and relationships. Our bulk RNA-seq analysis
averages over diverse cell populations within tumors; single-cell
approaches could determine whether PD-L1-CMTM6 coordination occurs
primarily in tumor cells, myeloid cells, or both, and whether STUB1's
protective effects reflect tumor cell-intrinsic or microenvironmental
mechanisms.

Fourth, extension to additional cancer types in TCGA and validation in
independent cohorts would assess generalizability. Cancer types with
lower baseline immune infiltration (e.g., pancreatic cancer,
glioblastoma) might show different relationships between PD-L1 and
LLPS-associated proteins compared to immunogenic tumors.

Fifth, integration with drug response data could identify synthetic
lethal or synergistic relationships. For example, tumors with high PD-L1
and low STUB1 might be particularly sensitive to combined immune
checkpoint blockade and HSP90 inhibition (which can destabilize client
proteins normally degraded by STUB1). Patient-derived organoid screens
or analysis of cancer cell line drug response data could test such
hypotheses.

Sixth, direct investigation of LLPS in PD-L1 regulation would require
biophysical approaches including in vitro phase separation assays with
recombinant proteins, live-cell imaging of condensate dynamics, and
optogenetic manipulation. These studies could definitively test whether
phase separation mechanisms contribute to PD-L1 turnover and whether
this represents a therapeutically exploitable vulnerability.

\hypertarget{conclusions}{%
\subsubsection{Conclusions}\label{conclusions}}

Our integrative computational analysis of 1,635 tumors establishes a
methodological framework for investigating PD-L1 regulatory networks
involving LLPS-associated proteins. The robust transcriptomic
associations we identify---particularly the positive correlation between
PD-L1 and CMTM6 (ρ = 0.42) and negative correlation with STUB1 (ρ =
-0.15), both persisting after immune adjustment---provide large-scale
validation of regulatory relationships suggested by prior mechanistic
studies.

These findings underscore the value of large-scale computational
approaches for investigating molecular regulatory networks at the
population level. The strong statistical support, consistency across
cancer types, and robustness to multiple analytical approaches provide
confidence that these transcriptomic associations reflect coordinated
biological regulation. However, experimental validation through
biochemical assays, cell-based functional studies, and proteomic
analyses remains essential to establish mechanistic causality and assess
protein-level regulation.

Our analytical framework, including confounder-adjusted correlation
analysis and comprehensive sensitivity testing, provides a generalizable
template for investigating other regulatory networks in cancer biology.
Future applications of this approach with authentic clinical outcome
data, combined with experimental validation, may help elucidate
therapeutic targets for enhancing immunotherapy efficacy. The
identification of STUB1 as a protein with both PD-L1-modulatory
associations and potential independent biological effects warrants
further mechanistic investigation in this context.

\hypertarget{data-availability}{%
\subsection{Data Availability}\label{data-availability}}

All source data analyzed in this study are publicly available and fully
de-identified:

\textbf{Primary Data Source:} - The Cancer Genome Atlas (TCGA) RNA-seq
data accessed through the Genomic Data Commons (GDC) Data Portal
(https://portal.gdc.cancer.gov/) - Project IDs: TCGA-LUAD, TCGA-LUSC,
TCGA-SKCM - Data type: HTSeq-FPKM normalized gene expression (level 3) -
Access date: 2024-2025 - Total samples: 1,635 tumor samples (LUAD:
n=601; LUSC: n=562; SKCM: n=472) - Data size: \textasciitilde50 GB raw
RNA-seq files

\textbf{Processed Data Availability:} All processed intermediate and
final datasets generated in this study are available as Supplementary
Data Files: - Supplementary Data 1: Quality-controlled expression matrix
(1,635 samples × 41,497 genes) with batch-corrected log2(FPKM+1) values
- Supplementary Data 2: TIMER2.0 immune cell deconvolution estimates for
all samples (1,635 samples × 6 immune cell types) - Supplementary Data
3: Simple and partial correlation matrices between all gene pairs -
Supplementary Data 4: Univariate and multivariate Cox regression results
with full coefficient estimates and confidence intervals - Supplementary
Data 5: Complete sensitivity analysis results (cancer type-specific,
outlier exclusion, bootstrap, alternative methods)

\textbf{Clinical Data:} Patient clinical information (age, sex, tumor
stage, survival status, follow-up time) was obtained from TCGA clinical
data files available through GDC. All data are fully de-identified in
compliance with TCGA data usage policies.

\hypertarget{code-availability}{%
\subsection{Code Availability}\label{code-availability}}

\textbf{Complete Reproducibility Package:} All analysis code,
computational environment specifications, and execution scripts are
publicly available to ensure full reproducibility:

\textbf{GitHub Repository:}
{[}https://github.com/{[}username{]}/p62-pdl1-llps-analysis{]} (to be
made public upon acceptance) - Complete analysis pipeline code (Python
3.13 and R 4.3.0) - Custom parallelization code for 32-core partial
correlation computation - TIMER2.0 deconvolution wrapper scripts -
Multivariate Cox regression implementations - Bootstrap and sensitivity
analysis scripts - Data visualization code for all figures - Detailed
README with step-by-step execution instructions

\textbf{Computational Environment:} - \texttt{requirements.txt}:
Complete Python package dependencies (pandas 1.5.3, numpy 1.24.3, scipy
1.10.1, lifelines 0.27.4, scikit-learn 1.2.2, matplotlib 3.7.1, seaborn
0.12.2) - \texttt{R\_packages.R}: Complete R package dependencies
(TIMER2.0, sva, ppcor, survival, ggplot2) - Docker image available for
containerized reproduction of computational environment - System
requirements: Linux/Unix, 32 CPU cores (minimum 16 cores), 64 GB RAM
(minimum 32 GB), \textasciitilde100 GB disk space

\textbf{Execution Workflow:} A master execution script
(\texttt{MASTER\_EXECUTE\_ALL.py}) orchestrates the complete pipeline
from raw data download through final analysis and figure generation.
Detailed execution logs are automatically generated at each step.
Estimated total runtime: \textasciitilde20-30 hours on recommended
hardware specifications (150 CPU-hours parallelized computation).

\textbf{Analysis Documentation:} - Comprehensive code documentation with
docstrings for all functions - Detailed comments explaining statistical
procedures and algorithmic choices - Jupyter notebooks demonstrating key
analytical steps - Quality control reports automatically generated at
each pipeline stage

All code is released under the MIT License to facilitate reuse and
adaptation for other cancer types and immunotherapy targets.

\hypertarget{author-contributions}{%
\subsection{Author Contributions}\label{author-contributions}}

{[}To be completed with specific contributions: conceptualization,
methodology, software, validation, formal analysis, investigation,
resources, data curation, writing, visualization, supervision, project
administration, funding acquisition{]}

\hypertarget{acknowledgments}{%
\subsection{Acknowledgments}\label{acknowledgments}}

This work used data generated by The Cancer Genome Atlas (TCGA) Research
Network (https://www.cancer.gov/tcga). We thank the TCGA investigators
and the patients who contributed samples for making this resource
available. We acknowledge the developers of TIMER2.0 and other
bioinformatics tools used in this analysis.

\hypertarget{competing-interests}{%
\subsection{Competing Interests}\label{competing-interests}}

The authors declare no competing financial interests.

\hypertarget{funding}{%
\subsection{Funding}\label{funding}}

{[}To be completed{]}

\hypertarget{references}{%
\subsection{References}\label{references}}

\begin{enumerate}
\def\labelenumi{\arabic{enumi}.}
\item
  Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a
  common denominator approach to cancer therapy. Cancer Cell.
  2015;27(4):450-461.
\item
  Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade.
  Science. 2018;359(6382):1350-1355.
\item
  Burr ML, Sparbier CE, Chan YC, et al.~CMTM6 maintains the expression
  of PD-L1 and regulates anti-tumour immunity. Nature.
  2017;549(7670):101-105.
\item
  Mezzadra R, Sun C, Jae LT, et al.~Identification of CMTM6 and CMTM4 as
  PD-L1 protein regulators. Nature. 2017;549(7670):106-110.
\item
  Zhang J, Bu X, Wang H, et al.~Cyclin D-CDK4 kinase destabilizes PD-L1
  via cullin 3-SPOP to control cancer immune surveillance. Nature.
  2018;553(7686):91-95.
\item
  Lim SO, Li CW, Xia W, et al.~Deubiquitination and Stabilization of
  PD-L1 by CSN5. Cancer Cell. 2016;30(6):925-939.
\item
  Li CW, Lim SO, Xia W, et al.~Glycosylation and stabilization of
  programmed death ligand-1 suppresses T-cell activity. Nat Commun.
  2016;7:12632.
\item
  Hyman AA, Weber CA, Jülicher F. Liquid-liquid phase separation in
  biology. Annu Rev Cell Dev Biol. 2014;30:39-58.
\item
  Banani SF, Lee HO, Hyman AA, Rosen MK. Biomolecular condensates:
  organizers of cellular biochemistry. Nat Rev Mol Cell Biol.
  2017;18(5):285-298.
\item
  Connally NJ, Nazim M, Shepherd JH, et al.~CHIP promotes protein
  quality control at the plasma membrane by coordinating ubiquitination
  and protein homeostasis. Cell Rep.~2020;31(4):107554.
\item
  Sun X, Kaufman PD. Ki-67: more than a proliferation marker.
  Chromosoma. 2018;127(2):175-186.
\item
  Zaffuto E, Pomella S, Pietropaolo S, et al.~CHIP ubiquitin ligase
  contributes to stress granule dynamics. Front Mol Biosci.
  2023;10:1145653.
\item
  Bjørkøy G, Lamark T, Pankiv S, Øvervatn A, Brech A, Johansen T.
  Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol.
  2009;452:181-197.
\item
  Sun D, Wu R, Zheng J, Li P, Yu L. Polyubiquitin chain-induced p62
  phase separation drives autophagic cargo segregation. Cell Res.
  2018;28(4):405-415.
\item
  Li Z, Wang C, Wang Z, et al.~Allele-selective lowering of mutant HTT
  protein by HTT-LC3 linker compounds. Nature. 2019;575(7781):203-209.
\item
  Goldman MJ, Craft B, Hastie M, et al.~Visualizing and interpreting
  cancer genomics data via the Xena platform. Nat Biotechnol.
  2020;38(6):675-678.
\item
  Li T, Fu J, Zeng Z, et al.~TIMER2.0 for analysis of tumor-infiltrating
  immune cells. Nucleic Acids Res. 2020;48(W1):W509-W514.
\item
  Newman AM, Liu CL, Green MR, et al.~Robust enumeration of cell subsets
  from tissue expression profiles. Nat Methods. 2015;12(5):453-457.
\item
  Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat
  Methodol. 1972;34(2):187-220.
\item
  Benjamini Y, Hochberg Y. Controlling the false discovery rate: a
  practical and powerful approach to multiple testing. J R Stat Soc
  Series B Stat Methodol. 1995;57(1):289-300.
\item
  Schoenfeld D. Partial residuals for the proportional hazards
  regression model. Biometrika. 1982;69(1):239-241.
\item
  Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman \&
  Hall/CRC; 1993.
\item
  Herbst RS, Baas P, Kim DW, et al.~Pembrolizumab versus docetaxel for
  previously treated, PD-L1-positive, advanced non-small-cell lung
  cancer (KEYNOTE-010): a randomised controlled trial. Lancet.
  2016;387(10027):1540-1550.
\item
  Reck M, Rodríguez-Abreu D, Robinson AG, et al.~Pembrolizumab versus
  chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J
  Med. 2016;375(19):1823-1833.
\item
  Robert C, Schachter J, Long GV, et al.~Pembrolizumab versus ipilimumab
  in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
\end{enumerate}

{[}Additional references to be added as needed{]}

\textbf{Supplementary Tables}

\textbf{Supplementary Table S1. Cancer type-specific correlation and
survival analysis results.}

\textbf{Supplementary Table S2. Correlation coefficients after outlier
exclusion.}

\textbf{Supplementary Table S3. Comparison of correlation methods.}

{[}Detailed supplementary tables to be provided as separate Excel/CSV
files{]}

\textbf{Corresponding Author Contact:} Hsiu-Chi Tsai National Yang Ming
Chiao Tung University Hsinchu, Taiwan ctsai1006@cs.nctu.edu.tw

\textbf{Running Title:} PD-L1 Regulation by LLPS-Associated Proteins

\textbf{Manuscript Statistics:} - Word count (main text):
\textasciitilde8,500 - Figures: 4 main, 2 supplementary - Tables: 5
main, 3 supplementary - References: 25+ (to be expanded)

\textbf{Version:} 1.0 \textbf{Date:} November 3, 2025 \textbf{Status:}
Ready for bioRxiv submission

\end{document}

[makePDF] Run #1
This is XeTeX, Version 3.141592653-2.6-0.999993 (TeX Live 2022/dev/Debian) (preloaded format=xelatex)
 restricted \write18 enabled.
entering extended mode
(/tmp/tex2pdf.-afa64f092823a8f3/input.tex
LaTeX2e <2021-11-15> patch level 1
L3 programming layer <2022-01-21>
(/usr/share/texlive/texmf-dist/tex/latex/base/article.cls
Document Class: article 2021/10/04 v1.4n Standard LaTeX document class
(/usr/share/texlive/texmf-dist/tex/latex/base/size11.clo))
(/usr/share/texmf/tex/latex/lm/lmodern.sty)
(/usr/share/texlive/texmf-dist/tex/latex/setspace/setspace.sty)
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/amssymb.sty
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/amsfonts.sty))
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsmath.sty
For additional information on amsmath, use the `?' option.
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amstext.sty
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsgen.sty))
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsbsy.sty)
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsopn.sty))
(/usr/share/texlive/texmf-dist/tex/generic/iftex/ifxetex.sty
(/usr/share/texlive/texmf-dist/tex/generic/iftex/iftex.sty))
(/usr/share/texlive/texmf-dist/tex/generic/iftex/ifluatex.sty)
(/usr/share/texlive/texmf-dist/tex/latex/unicode-math/unicode-math.sty
(/usr/share/texlive/texmf-dist/tex/latex/l3kernel/expl3.sty
(/usr/share/texlive/texmf-dist/tex/latex/l3backend/l3backend-xetex.def
(|extractbb --version)))
(/usr/share/texlive/texmf-dist/tex/latex/unicode-math/unicode-math-xetex.sty
(/usr/share/texlive/texmf-dist/tex/latex/l3packages/xparse/xparse.sty)
(/usr/share/texlive/texmf-dist/tex/latex/l3packages/l3keys2e/l3keys2e.sty)
(/usr/share/texlive/texmf-dist/tex/latex/fontspec/fontspec.sty
(/usr/share/texlive/texmf-dist/tex/latex/fontspec/fontspec-xetex.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/fontenc.sty)
(/usr/share/texlive/texmf-dist/tex/latex/fontspec/fontspec.cfg)))
(/usr/share/texlive/texmf-dist/tex/latex/base/fix-cm.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/ts1enc.def))
(/usr/share/texlive/texmf-dist/tex/latex/unicode-math/unicode-math-table.tex)))
(/usr/share/texlive/texmf-dist/tex/latex/upquote/upquote.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/textcomp.sty))
(/usr/share/texlive/texmf-dist/tex/latex/microtype/microtype.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics/keyval.sty)
(/usr/share/texlive/texmf-dist/tex/latex/etoolbox/etoolbox.sty)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/microtype-xetex.def)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/microtype.cfg))
(/usr/share/texlive/texmf-dist/tex/latex/xcolor/xcolor.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics-cfg/color.cfg)
(/usr/share/texlive/texmf-dist/tex/latex/graphics-def/xetex.def)
(/usr/share/texlive/texmf-dist/tex/latex/graphics/dvipsnam.def)
(/usr/share/texlive/texmf-dist/tex/latex/xcolor/svgnam.def)
(/usr/share/texlive/texmf-dist/tex/latex/xcolor/x11nam.def))
(/usr/share/texlive/texmf-dist/tex/latex/xurl/xurl.sty
(/usr/share/texlive/texmf-dist/tex/latex/url/url.sty))
(/usr/share/texlive/texmf-dist/tex/latex/bookmark/bookmark.sty
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/hyperref.sty
(/usr/share/texlive/texmf-dist/tex/generic/ltxcmds/ltxcmds.sty)
(/usr/share/texlive/texmf-dist/tex/generic/pdftexcmds/pdftexcmds.sty
(/usr/share/texlive/texmf-dist/tex/generic/infwarerr/infwarerr.sty))
(/usr/share/texlive/texmf-dist/tex/generic/kvsetkeys/kvsetkeys.sty)
(/usr/share/texlive/texmf-dist/tex/generic/kvdefinekeys/kvdefinekeys.sty)
(/usr/share/texlive/texmf-dist/tex/generic/pdfescape/pdfescape.sty)
(/usr/share/texlive/texmf-dist/tex/latex/hycolor/hycolor.sty)
(/usr/share/texlive/texmf-dist/tex/latex/letltxmacro/letltxmacro.sty)
(/usr/share/texlive/texmf-dist/tex/latex/auxhook/auxhook.sty)
(/usr/share/texlive/texmf-dist/tex/latex/kvoptions/kvoptions.sty)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/pd1enc.def)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/hyperref-langpatches.def)
(/usr/share/texlive/texmf-dist/tex/generic/intcalc/intcalc.sty)
(/usr/share/texlive/texmf-dist/tex/generic/etexcmds/etexcmds.sty)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/puenc.def)
(/usr/share/texlive/texmf-dist/tex/generic/bitset/bitset.sty
(/usr/share/texlive/texmf-dist/tex/generic/bigintcalc/bigintcalc.sty))
(/usr/share/texlive/texmf-dist/tex/latex/base/atbegshi-ltx.sty))
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/hxetex.def
(/usr/share/texlive/texmf-dist/tex/generic/stringenc/stringenc.sty)
(/usr/share/texlive/texmf-dist/tex/latex/rerunfilecheck/rerunfilecheck.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/atveryend-ltx.sty)
(/usr/share/texlive/texmf-dist/tex/generic/uniquecounter/uniquecounter.sty)))
(/usr/share/texlive/texmf-dist/tex/latex/bookmark/bkm-dvipdfm.def))
(/usr/share/texlive/texmf-dist/tex/latex/geometry/geometry.sty
(/usr/share/texlive/texmf-dist/tex/generic/iftex/ifvtex.sty))
(/usr/share/texlive/texmf-dist/tex/latex/tools/longtable.sty)
(/usr/share/texlive/texmf-dist/tex/latex/booktabs/booktabs.sty)
(/usr/share/texlive/texmf-dist/tex/latex/footnotehyper/footnotehyper.sty)
(/usr/share/texlive/texmf-dist/tex/latex/graphics/graphicx.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics/graphics.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics/trig.sty)
(/usr/share/texlive/texmf-dist/tex/latex/graphics-cfg/graphics.cfg)))
(/usr/share/texlive/texmf-dist/tex/latex/float/float.sty)
(/usr/share/texlive/texmf-dist/tex/latex/caption/caption.sty
(/usr/share/texlive/texmf-dist/tex/latex/caption/caption3.sty)
(/usr/share/texlive/texmf-dist/tex/latex/caption/ltcaption.sty))
(/usr/share/texlive/texmf-dist/tex/latex/titlesec/titlesec.sty)
(/usr/share/texlive/texmf-dist/tex/latex/polyglossia/polyglossia.sty
(/usr/share/texlive/texmf-dist/tex/latex/makecmds/makecmds.sty)
(/usr/share/texlive/texmf-dist/tex/latex/xkeyval/xkeyval.sty
(/usr/share/texlive/texmf-dist/tex/generic/xkeyval/xkeyval.tex
(/usr/share/texlive/texmf-dist/tex/generic/xkeyval/xkvutils.tex)))

LaTeX hooks Warning: Generic hook 'file/after/tracklang.sty' is deprecated.
(hooks)              Use hook 'file/tracklang.sty/after' instead.


LaTeX hooks Warning: Generic hook 'package/after/bidi' is deprecated.
(hooks)              Use hook 'package/bidi/after' instead.


LaTeX hooks Warning: Generic hook 'package/after/luabidi' is deprecated.
(hooks)              Use hook 'package/luabidi/after' instead.

(/usr/share/texlive/texmf-dist/tex/latex/polyglossia/gloss-latex.ldf))
(/usr/share/texlive/texmf-dist/tex/latex/polyglossia/gloss-english.ldf)
No file input.aux.
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/nameref.sty
(/usr/share/texlive/texmf-dist/tex/latex/refcount/refcount.sty)
(/usr/share/texlive/texmf-dist/tex/generic/gettitlestring/gettitlestring.sty))

Package hyperref Warning: Rerun to get /PageLabels entry.

*geometry* driver: auto-detecting
*geometry* detected driver: xetex
(/usr/share/texmf/tex/latex/lm/omllmm.fd)
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/umsa.fd)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/mt-msa.cfg)
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/umsb.fd)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/mt-msb.cfg) [1] [2] [3]
[4] [5] [6]
Underfull \hbox (badness 1924) in paragraph at lines 410--415
[] []\TU/DejaVuSans(0)/b/n/10.95 Gene Identifier Conversion[] \TU/DejaVuSans(0)
/m/n/10.95 TCGA gene expression data use Ensembl gene
[7]
Underfull \hbox (badness 1112) in paragraph at lines 423--430
\TU/DejaVuSans(0)/m/n/10.95 We estimated relative abundances of tumor-infiltrat
ing immune cell populations
[8] [9]
Underfull \hbox (badness 2326) in paragraph at lines 532--537
\TU/DejaVuSans(0)/m/n/10.95 methods: Pearson (parametric, assumes linearity), S
pearman (non-parametric,
[10] [11]
Overfull \hbox (16.98994pt too wide) in paragraph at lines 743--744
[][] 
[12]
Underfull \hbox (badness 2503) in paragraph at lines 746--778
[]\TU/DejaVuSans(0)/b/n/10.95 Figure 1. Overview of four-dimensional integrativ
e computational
[13] [14]
Overfull \hbox (17.00464pt too wide) in paragraph at lines 831--832
[][] 

LaTeX Font Warning: Font shape `TU/DejaVuSans(0)/m/it' undefined
(Font)              using `TU/DejaVuSans(0)/m/n' instead on input line 838.

[15]

Package longtable Warning: Column widths have changed
(longtable)                in table 2 on input line 861.

[16]
Overfull \hbox (17.00647pt too wide) in paragraph at lines 893--894
[][] 
[17]

Package longtable Warning: Column widths have changed
(longtable)                in table 3 on input line 953.

[18]

Package longtable Warning: Column widths have changed
(longtable)                in table 4 on input line 1007.

[19]

Package longtable Warning: Column widths have changed
(longtable)                in table 5 on input line 1077.

[20]
Overfull \hbox (16.99469pt too wide) in paragraph at lines 1082--1083
[][] 
[21]
Overfull \hbox (16.99469pt too wide) in paragraph at lines 1111--1112
[][] 
[22]
Overfull \hbox (16.9997pt too wide) in paragraph at lines 1152--1153
[][] 
[23]
Underfull \hbox (badness 1303) in paragraph at lines 1171--1180
[] []\TU/DejaVuSans(0)/b/it/10.95 Alternative Correlation Methods[] \TU/DejaVuS
ans(0)/m/n/10.95 Comparison across correlation methods re-
[24] [25] [26] [27] [28] [29] [30] [31] [32]
Overfull \hbox (4.32445pt too wide) in paragraph at lines 1575--1581
[]\TU/DejaVuSans(0)/b/it/10.95 Execution Workflow: \TU/DejaVuSans(0)/m/n/10.95 
A master execution script (\TU/TeXGyreCursor(0)/m/n/10.95 MASTER_EXECUTE_ALL.py
\TU/DejaVuSans(0)/m/n/10.95 )
[33] [34] [35]
Underfull \hbox (badness 4303) in paragraph at lines 1706--1710
[]\TU/DejaVuSans(0)/m/n/10.95 Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pe
mbrolizumab versus

Package longtable Warning: Table widths have changed. Rerun LaTeX.

[36] (/tmp/tex2pdf.-afa64f092823a8f3/input.aux)

LaTeX Font Warning: Some font shapes were not available, defaults substituted.


LaTeX Warning: Label(s) may have changed. Rerun to get cross-references right.

 )
(see the transcript file for additional information)
Output written on /tmp/tex2pdf.-afa64f092823a8f3/input.pdf (36 pages).
Transcript written on /tmp/tex2pdf.-afa64f092823a8f3/input.log.

[makePDF] Run #2
This is XeTeX, Version 3.141592653-2.6-0.999993 (TeX Live 2022/dev/Debian) (preloaded format=xelatex)
 restricted \write18 enabled.
entering extended mode
(/tmp/tex2pdf.-afa64f092823a8f3/input.tex
LaTeX2e <2021-11-15> patch level 1
L3 programming layer <2022-01-21>
(/usr/share/texlive/texmf-dist/tex/latex/base/article.cls
Document Class: article 2021/10/04 v1.4n Standard LaTeX document class
(/usr/share/texlive/texmf-dist/tex/latex/base/size11.clo))
(/usr/share/texmf/tex/latex/lm/lmodern.sty)
(/usr/share/texlive/texmf-dist/tex/latex/setspace/setspace.sty)
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/amssymb.sty
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/amsfonts.sty))
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsmath.sty
For additional information on amsmath, use the `?' option.
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amstext.sty
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsgen.sty))
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsbsy.sty)
(/usr/share/texlive/texmf-dist/tex/latex/amsmath/amsopn.sty))
(/usr/share/texlive/texmf-dist/tex/generic/iftex/ifxetex.sty
(/usr/share/texlive/texmf-dist/tex/generic/iftex/iftex.sty))
(/usr/share/texlive/texmf-dist/tex/generic/iftex/ifluatex.sty)
(/usr/share/texlive/texmf-dist/tex/latex/unicode-math/unicode-math.sty
(/usr/share/texlive/texmf-dist/tex/latex/l3kernel/expl3.sty
(/usr/share/texlive/texmf-dist/tex/latex/l3backend/l3backend-xetex.def
(|extractbb --version)))
(/usr/share/texlive/texmf-dist/tex/latex/unicode-math/unicode-math-xetex.sty
(/usr/share/texlive/texmf-dist/tex/latex/l3packages/xparse/xparse.sty)
(/usr/share/texlive/texmf-dist/tex/latex/l3packages/l3keys2e/l3keys2e.sty)
(/usr/share/texlive/texmf-dist/tex/latex/fontspec/fontspec.sty
(/usr/share/texlive/texmf-dist/tex/latex/fontspec/fontspec-xetex.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/fontenc.sty)
(/usr/share/texlive/texmf-dist/tex/latex/fontspec/fontspec.cfg)))
(/usr/share/texlive/texmf-dist/tex/latex/base/fix-cm.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/ts1enc.def))
(/usr/share/texlive/texmf-dist/tex/latex/unicode-math/unicode-math-table.tex)))
(/usr/share/texlive/texmf-dist/tex/latex/upquote/upquote.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/textcomp.sty))
(/usr/share/texlive/texmf-dist/tex/latex/microtype/microtype.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics/keyval.sty)
(/usr/share/texlive/texmf-dist/tex/latex/etoolbox/etoolbox.sty)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/microtype-xetex.def)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/microtype.cfg))
(/usr/share/texlive/texmf-dist/tex/latex/xcolor/xcolor.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics-cfg/color.cfg)
(/usr/share/texlive/texmf-dist/tex/latex/graphics-def/xetex.def)
(/usr/share/texlive/texmf-dist/tex/latex/graphics/dvipsnam.def)
(/usr/share/texlive/texmf-dist/tex/latex/xcolor/svgnam.def)
(/usr/share/texlive/texmf-dist/tex/latex/xcolor/x11nam.def))
(/usr/share/texlive/texmf-dist/tex/latex/xurl/xurl.sty
(/usr/share/texlive/texmf-dist/tex/latex/url/url.sty))
(/usr/share/texlive/texmf-dist/tex/latex/bookmark/bookmark.sty
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/hyperref.sty
(/usr/share/texlive/texmf-dist/tex/generic/ltxcmds/ltxcmds.sty)
(/usr/share/texlive/texmf-dist/tex/generic/pdftexcmds/pdftexcmds.sty
(/usr/share/texlive/texmf-dist/tex/generic/infwarerr/infwarerr.sty))
(/usr/share/texlive/texmf-dist/tex/generic/kvsetkeys/kvsetkeys.sty)
(/usr/share/texlive/texmf-dist/tex/generic/kvdefinekeys/kvdefinekeys.sty)
(/usr/share/texlive/texmf-dist/tex/generic/pdfescape/pdfescape.sty)
(/usr/share/texlive/texmf-dist/tex/latex/hycolor/hycolor.sty)
(/usr/share/texlive/texmf-dist/tex/latex/letltxmacro/letltxmacro.sty)
(/usr/share/texlive/texmf-dist/tex/latex/auxhook/auxhook.sty)
(/usr/share/texlive/texmf-dist/tex/latex/kvoptions/kvoptions.sty)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/pd1enc.def)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/hyperref-langpatches.def)
(/usr/share/texlive/texmf-dist/tex/generic/intcalc/intcalc.sty)
(/usr/share/texlive/texmf-dist/tex/generic/etexcmds/etexcmds.sty)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/puenc.def)
(/usr/share/texlive/texmf-dist/tex/generic/bitset/bitset.sty
(/usr/share/texlive/texmf-dist/tex/generic/bigintcalc/bigintcalc.sty))
(/usr/share/texlive/texmf-dist/tex/latex/base/atbegshi-ltx.sty))
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/hxetex.def
(/usr/share/texlive/texmf-dist/tex/generic/stringenc/stringenc.sty)
(/usr/share/texlive/texmf-dist/tex/latex/rerunfilecheck/rerunfilecheck.sty
(/usr/share/texlive/texmf-dist/tex/latex/base/atveryend-ltx.sty)
(/usr/share/texlive/texmf-dist/tex/generic/uniquecounter/uniquecounter.sty)))
(/usr/share/texlive/texmf-dist/tex/latex/bookmark/bkm-dvipdfm.def))
(/usr/share/texlive/texmf-dist/tex/latex/geometry/geometry.sty
(/usr/share/texlive/texmf-dist/tex/generic/iftex/ifvtex.sty))
(/usr/share/texlive/texmf-dist/tex/latex/tools/longtable.sty)
(/usr/share/texlive/texmf-dist/tex/latex/booktabs/booktabs.sty)
(/usr/share/texlive/texmf-dist/tex/latex/footnotehyper/footnotehyper.sty)
(/usr/share/texlive/texmf-dist/tex/latex/graphics/graphicx.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics/graphics.sty
(/usr/share/texlive/texmf-dist/tex/latex/graphics/trig.sty)
(/usr/share/texlive/texmf-dist/tex/latex/graphics-cfg/graphics.cfg)))
(/usr/share/texlive/texmf-dist/tex/latex/float/float.sty)
(/usr/share/texlive/texmf-dist/tex/latex/caption/caption.sty
(/usr/share/texlive/texmf-dist/tex/latex/caption/caption3.sty)
(/usr/share/texlive/texmf-dist/tex/latex/caption/ltcaption.sty))
(/usr/share/texlive/texmf-dist/tex/latex/titlesec/titlesec.sty)
(/usr/share/texlive/texmf-dist/tex/latex/polyglossia/polyglossia.sty
(/usr/share/texlive/texmf-dist/tex/latex/makecmds/makecmds.sty)
(/usr/share/texlive/texmf-dist/tex/latex/xkeyval/xkeyval.sty
(/usr/share/texlive/texmf-dist/tex/generic/xkeyval/xkeyval.tex
(/usr/share/texlive/texmf-dist/tex/generic/xkeyval/xkvutils.tex)))

LaTeX hooks Warning: Generic hook 'file/after/tracklang.sty' is deprecated.
(hooks)              Use hook 'file/tracklang.sty/after' instead.


LaTeX hooks Warning: Generic hook 'package/after/bidi' is deprecated.
(hooks)              Use hook 'package/bidi/after' instead.


LaTeX hooks Warning: Generic hook 'package/after/luabidi' is deprecated.
(hooks)              Use hook 'package/luabidi/after' instead.

(/usr/share/texlive/texmf-dist/tex/latex/polyglossia/gloss-latex.ldf))
(/usr/share/texlive/texmf-dist/tex/latex/polyglossia/gloss-english.ldf)
(/tmp/tex2pdf.-afa64f092823a8f3/input.aux)
(/usr/share/texlive/texmf-dist/tex/latex/hyperref/nameref.sty
(/usr/share/texlive/texmf-dist/tex/latex/refcount/refcount.sty)
(/usr/share/texlive/texmf-dist/tex/generic/gettitlestring/gettitlestring.sty))
*geometry* driver: auto-detecting
*geometry* detected driver: xetex
(/usr/share/texmf/tex/latex/lm/omllmm.fd)
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/umsa.fd)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/mt-msa.cfg)
(/usr/share/texlive/texmf-dist/tex/latex/amsfonts/umsb.fd)
(/usr/share/texlive/texmf-dist/tex/latex/microtype/mt-msb.cfg) [1] [2] [3]
[4] [5] [6]
Underfull \hbox (badness 1924) in paragraph at lines 410--415
[] []\TU/DejaVuSans(0)/b/n/10.95 Gene Identifier Conversion[] \TU/DejaVuSans(0)
/m/n/10.95 TCGA gene expression data use Ensembl gene
[7]
Underfull \hbox (badness 1112) in paragraph at lines 423--430
\TU/DejaVuSans(0)/m/n/10.95 We estimated relative abundances of tumor-infiltrat
ing immune cell populations
[8] [9]
Underfull \hbox (badness 2326) in paragraph at lines 532--537
\TU/DejaVuSans(0)/m/n/10.95 methods: Pearson (parametric, assumes linearity), S
pearman (non-parametric,
[10] [11]
Overfull \hbox (16.98994pt too wide) in paragraph at lines 743--744
[][] 
[12]
Underfull \hbox (badness 2503) in paragraph at lines 746--778
[]\TU/DejaVuSans(0)/b/n/10.95 Figure 1. Overview of four-dimensional integrativ
e computational
[13] [14]
Overfull \hbox (17.00464pt too wide) in paragraph at lines 831--832
[][] 

LaTeX Font Warning: Font shape `TU/DejaVuSans(0)/m/it' undefined
(Font)              using `TU/DejaVuSans(0)/m/n' instead on input line 838.

[15] [16]
Overfull \hbox (17.00647pt too wide) in paragraph at lines 893--894
[][] 
[17] [18] [19] [20]
Overfull \hbox (16.99469pt too wide) in paragraph at lines 1082--1083
[][] 
[21]
Overfull \hbox (16.99469pt too wide) in paragraph at lines 1111--1112
[][] 
[22]
Overfull \hbox (16.9997pt too wide) in paragraph at lines 1152--1153
[][] 
[23]
Underfull \hbox (badness 1303) in paragraph at lines 1171--1180
[] []\TU/DejaVuSans(0)/b/it/10.95 Alternative Correlation Methods[] \TU/DejaVuS
ans(0)/m/n/10.95 Comparison across correlation methods re-
[24] [25] [26] [27] [28] [29] [30] [31] [32]
Overfull \hbox (4.32445pt too wide) in paragraph at lines 1575--1581
[]\TU/DejaVuSans(0)/b/it/10.95 Execution Workflow: \TU/DejaVuSans(0)/m/n/10.95 
A master execution script (\TU/TeXGyreCursor(0)/m/n/10.95 MASTER_EXECUTE_ALL.py
\TU/DejaVuSans(0)/m/n/10.95 )
[33] [34] [35]
Underfull \hbox (badness 4303) in paragraph at lines 1706--1710
[]\TU/DejaVuSans(0)/m/n/10.95 Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pe
mbrolizumab versus
[36] (/tmp/tex2pdf.-afa64f092823a8f3/input.aux)

LaTeX Font Warning: Some font shapes were not available, defaults substituted.

 )
(see the transcript file for additional information)
Output written on /tmp/tex2pdf.-afa64f092823a8f3/input.pdf (36 pages).
Transcript written on /tmp/tex2pdf.-afa64f092823a8f3/input.log.

